Patent Publication Number: US-10776890-B1

Title: Generation from data threats and predictive application of the data models

Description:
FIELD 
     The field relates to the technical fields related to detection of nefarious acts related to data in a database, which can generate models to predict the nefarious acts, and more specifically, the models can be to detection of fraud, waste or abuse of pharmaceuticals at various steps in the pharmaceutical supply chain. 
     BACKGROUND 
     A tremendous amount of transaction and interaction data is collected by a number of different entities. Often, the data is overwhelming to intake, process, analyze. That is, the amount of data (medical or pharmacy) was too large to derive meaningful information to adequately detect fraud, waste or abuse in medical services or pharmaceutical services. Nonetheless, the data in the field of healthcare should be analyzed to check for potential fraud, waste or abuse. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1A  is a diagram of a data threat evaluation system, according to an example embodiment. 
         FIG. 1B  is a block diagram of an example system for data thread evaluation for model determination and calculation of risk scores using the models, according to an example embodiment; 
         FIG. 2  is a block diagram of an example data query device that may be deployed within the system of  FIGS. 1A and 1B , according to an example embodiment; 
         FIG. 3  is a block diagram of an example data manager device that may be deployed within the system of  FIGS. 1A and 1B , according to an example embodiment; 
         FIG. 4  is a block diagram of an example data analysis device that may be deployed within the system of  FIGS. 1A and 1B , according to an example embodiment; 
         FIG. 5  is a block diagram of an example benefit manager device that may be deployed within the system of  FIGS. 1A and 1B , according to an example embodiment; 
         FIG. 6  is a block diagram of an example the model database that may be deployed within the system of  FIGS. 1A and 1B , according to an example embodiment; 
         FIG. 7  is a block diagram of models and risk score types that may be deployed within a system as described herein, according to an example embodiment; 
         FIG. 8  is a block diagram of factors that can be input into the present systems and methods to determine a risk score, according to an example embodiment; 
         FIG. 9  is an example system for determining a fraud, waste or abuse score, according to an example embodiment; 
         FIGS. 10A-10E  show various fraud, waste or abuse risk score of a prescription drug, according to an example embodiment; 
         FIG. 11  is an example process flow illustrating methods for purchase evaluation, according to example embodiments; 
         FIG. 12  is an example process flow illustrating a method for investigating fraud, waste or abuse, according to an example embodiment; 
         FIG. 13  is a block diagram of an example transformation subsystem that may be deployed within the query device of  FIG. 2 , the data manager device of  FIG. 3 , the data analysis device of  FIG. 4 , or the benefit manager device of  FIG. 5 , according to an example embodiment; 
         FIG. 14  is an example process flow illustrating a method for investigating fraud, waste or abuse, according to an example embodiment; 
         FIG. 15  is a system for determining FWA risk models, according to an example embodiments; 
         FIG. 16  is a schematic view of data types that can be part of the claims data, according to an example embodiment; 
         FIG. 17  is a schematic view for determining a predictive model risk score, according to an example embodiment; and 
         FIG. 18  is a schematic view of model types that can be generated using the methods and systems herein, according to an example embodiment. 
     
    
    
     DETAILED DESCRIPTION 
     Example systems and methods for determining and using variable threat values, e.g., risk scores, for identifying likelihood of threats based on data. The threats can include, but are not limited to fraud, waste or abuse occurring in healthcare or pharmaceutical care. The variable threat value can be determined using the data related to processing prescriptions, including adjudication or delivery of prescriptions. Models are developed that allow the variable threat value to be computed. The threat models may be run on a data set or a subset of data that correlate to fraud, waste or abuse. The variable threat value can provide a quantified value that represents a likelihood a threat for various basis using different features selected from a same database with a global set of data types. The variable threat value can be compared to other variable threat value or threat thresholds to focus efforts in investigating potential threats, e.g., fraud, waste and abuse. 
     The data threat regression models use features that are identified as types of data in the database, e.g., prescription data or healthcare data that indicate or influence the likelihood of fraud, waste or abuse. The features are identified as those that are indicative of possible FWA in an example. The features can be identified from a known threat, e.g., a known incidence of FWA. Various statistical analysis can be performed to determine the data types in the database that are indicative of a potential threat. These data types can be used as features. The features are fewer than the total number of data types in the global database. That is, the system reduces the data types and only includes those that indicate a threat as features in the predictive threat model(s). The model(s) is then used to calculate a variable threat value. 
     When the variable threat value(s) are determined, then the variable threat value or changes in variable threat values over time may be used to trigger a flag, which may be sent to remote computer. The flag is an indicator that a potential threat, based on the underlying data is more likely than other scenarios. An investigation can be started when the flag is accepted. 
     In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of example embodiments. It will be evident, however, to one of ordinary skill in the art that embodiments of the invention may be practiced without these specific details. 
     The methods and systems may be used to maintain records or other data on certain persons and entities to use the data to determine potential for a threat, e.g., a fraud, waste or abuse threat. The potential can be identified as a variable threat value or a risk score. The variable threat value can be associated with a pharmacy, a patient, a prescriber (e.g., a doctor, a physician&#39;s assist, a nurse, a pharmacist and the like), or combinations thereof. In the context of healthcare, and prescription drugs more specifically, master records may be maintained on prescribers, pharmacies, and patients. These records contain certain information about these healthcare participants including name, address, phone number, and the like, and claim adjudication data associated with filling the prescription. The data can be selected and filtered to use a subset of the data that indicates possible threats, e.g., fraud, waste or abuse (FWA). The subset data is used to compute the variable threat value. The variable threat value can be used to determine if the threat has exceeded a threat threshold. In an example embodiment, a threat alert can be created and sent to client computer. 
     In addition to maintaining the master records, the development of the master records enable insights into what would otherwise be disparate information and thereby enable accurate viewing and other utilizations of relevant threats or risk, relevant prescription drug claims, medical claims, and the like. The master record can be used to compute variable threat values, e.g., risk scores based on an individual (e.g., a patient), a script filler (e.g., a pharmacy) or a script originator (e.g., a prescriber, doctor, nurse, pharmacist and anyone licensed to write a script). 
     In some embodiments, the methods and systems enable integration of provider information, prescription claims, patient information and medical claims to identify risk, develop risk scores, links and relationships between individual providers, provider organizations, health plans and accountable care organizations (ACOs), provider networks, and patients, any of which may be used to further refine a risk score or identify additional risks of fraud, waste or abuse of the prescription drug system. Risk scores can also include profiling and benchmarking of pharmacies, patients and doctors using various factors, including therapeutic class, patient demographics, brand and generic drugs, specialty drugs and compounds, and mail versus retail channel, may be performed. Utilization and cost may be identified, thereby enabling optimization of provider networks and ACOS, Medicare and Medicaid opportunities, and fraud, waste, and abuse detection. The risk scores can be determined by predictive models that use only subsets of the data types available with the data set, e.g., prescription claims data, medical services data and the like. 
       FIG. 1A  is a schematic view of a data threat evaluation system  100 A that includes a data storage device  116  in communication with a data model structure  103 . The data storage device  116  includes circuitry to store a plurality of data types that can be broken down into subgroupings of data types, e.g., a first data subset that relate to a threat and a second data subset that do not relate to the threat. The data model structure  101  is configured to interact with the database in the data storage device  116  to develop models from the database  116 , which could not be developed by people due to the complexity and quantity of data types and data. The data model structure  101  includes a root object query  103  that, when executed, returns a third data subset from the plurality of data types that predate a known threat, the third data subset including data types in both the first data subset and the second data subset. The data model structure includes a model schema  105  to extract, from the third data subset identified by the root object query  103 , data types of the first subset that predicate and indicate the threat. The model schema  105  produces at least an individualized data threat regression model  109 , a script originator regression model  111 , and a script filler data threat regression model  113  using the extracted data types. The data types selected by the model schema  105  act as features that can be used to indicate a possible threat, e.g., by computing a variable threat value. The model schema  105  may operate to identify types of data in the third data subset that indicate at least one of fraud, waste, abuse, or a combination thereof by a patient, wherein the types of data indicate at least one of fraud, waste, abuse, or a combination thereof are fewer than all types of data. 
     The data storage device  116  may store a plurality of data threat regression models including an individualized data threat regression model  109 , a script originator regression model  111 , and a script filler data threat regression model  113 . These models  109 ,  111 ,  113  can be derived from statistically significant script data types working backward from known threats as indicated in the data model structure  101 . 
     A processor  107 , which includes electronic circuitry, can load one of the individualized data threat regression model  109 , the script originator regression model  111 , and the script filler data threat regression model  113 . The models can be stored in a separate model storage, e.g., a data base separate from the data storage system  116  or in the model schema  105 . The processor  107  accesses the data model structure  101  to receive or to apply at least one of the individualized data threat regression model, the script originator regression model and the script filler data threat regression model to data in the data storage device to identify potential threats by calculating a variable value produced by at least one of the individualized data threat regression model, the script originator regression model and the script filler data threat regression model. The processor  107  may be configured to generate an individualized data threat variable value over a first-time segment using the individualized data threat regression model and claims data in the data storage device  116 . The processor  107  may be configured to generate a script originator data threat variable value over a second-time segment using the script originator regression model and the claims data in the data storage device  116 . The processor  107  may be configured to generate a script filler data threat variable value over a third-time segment using the script filler data threat regression model and the claims data in the data storage device  116 . The processor  107  may be configured to determine violation of a data threat threshold by at least one of the patient data threat variable value, the prescriber data threat variable value, and the pharmacy data threat variable value. The data threat threshold can be a value relative to other values generated by a same model or a set value that when exceeded or met indicates a likelihood of a data threat, fraud waste or abuse in a prescription drug system. 
     The model schema  105  may operate on the first data subset to identify data types that indicate opioid threats, e.g., fraud, waste or abuse of opioids or like drugs. In an example, the model schema  105  identifies the threat regression models as opioid models for the individual, the script originator and/or the script filler. The model schema  105  may identify as features for models. Examples of features that are extracted from the database by the model schema include, in an example embodiment, at least one of a benzodiazepine consumption feature, a number of unique prescriber and pharmacy combinations per therapy feature, a morphine equivalent dose feature, an opioid claims per pharmacy feature, a refill too soon reject transactions feature, a paid claim amount feature, a sleep claims per pharmacy feature, a number of days between earliest opioid fill and most recent opioid fill feature, a distance traveled for opioids feature, a duplicate therapy claims feature, a number of unique prescribers for control substances feature, a concomitant opioid and suboxone consumption feature, a brand claims, feature a chain pharmacy usage feature, a control substances feature, an emergency room prescriber usage feature, a night claims feature, a claims where the pharmacy and doctor are not in the same state feature, a number of submitted and then reversed transactions feature, or combinations thereof. There are certain data types that are not indicative of a threat. These data types may include an age data type, a prior authorizations data type, a specialty drug claims data type, a maintenance utilization data type, a gender data type, a line of business data type, a name data type, as features. 
     In an example embodiment, the processor  107  can load one of the plurality of data threat regression models and accessing a script source database to select an individualized data threat regression model  109 , a script originator regression model  111  and a script filler data threat regression model  113  from the plurality of data threat regression models based on a type of data threat processing evaluation being determined. The processor  107  can reduce the statistically significant script data types stored in the script source database by including only the statistically significant data script types that indicate threats and generate variable values indicative of a threat. The processor  107  can determine an individualized data threat variable value over a first-time segment using the individualized data threat regression model  109  and claims data in the script source database, which can be part of data storage device  116 . The processor  107  can generate a script originator data threat variable value over a second-time segment using the script originator regression model  111  and the claims data. The processor  107  can generate a script filler data threat variable value over a third-time segment using the script filler data threat regression model  113  and the claims data. The processor  107  can determine violation of a data threat threshold by at least one of the patient data threat variable value, the prescriber data threat variable value, and the pharmacy data threat variable value. 
     The data threat evaluation system  100  can further output a notifier that a variable value has exceeded a threshold for any individual variable value that is calculated using, at least in part, the models. The processor  107  can send a risk flag to a client device when a risk threshold violation by at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value is determined. The processor  107  wirelessly transmits the risk flag to the client device. The processor  107  is to receive a reply from the client device to trigger a threat investigation. The processor  107  is to determine a violation of a data threat threshold by determining if a rate of change of a data threat variable value from at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value over a fourth-time period exceed a rate threshold. The processor  107  can also determine the violation of a data threat variable value from at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value and audit discrepancies both increase at a first rate and a second rate, respectively. The processor  107  can determine a data threat variable value from at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value after a pharmacy benefit manager intervention with an increasing amount of billings after a pharmacy benefit manager intervention. The processor  170  can determine a violation of a risk threshold includes an increasing threat variable value from at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value and an increasing number of prescription drug claims. 
     The data threat evaluation system  100 A can trigger a viewer to load an application to a client device. The viewer application can be stored in a database, e.g., the database devices  114 ,  116  or the like, and sent over a communication network, e.g., network  104 , to a device, e.g., devices  102 ,  106 ,  108 ,  110 . The viewer application is configured to provide a graphical user interface to show a threat notification, e.g., a risk score flag and/or a data threat variable value from at least one of the individualized data threat variable value, the script originator data threat variable value, and the script filler data threat variable value, or combinations thereof. The viewer application is further configured to receive an input to trigger an investigation and send the trigger to a pharmacy benefits manager device. This trigger can be a signal sent from the device running the viewer application over the network back to the database device  114 ,  116  or another operational device. 
     The model schema  105  is to select data types as features for a threat model that indicate or influence a possible threat and are fewer than the total number of data types in the database being investigated for threats. In an example, embodiment, the individualized data threat regression model includes features from statistically significant script data types to calculate the variable value with a number of the features being less than one-third of types of data in the data storage device. The individualized data threat regression model includes individualized model features that are fewer than a number of data types in the data storage device. The script originator regression model includes script model features that are fewer than the number of data types in the data storage device. The script filler data threat regression model includes script filler model features that are fewer than the number of data types in the data storage device. The model schema  105  is to extract the individualized model features, the script model features, the script filler model features from a database in the data storage device. The individualized model features indicate a threat by an individual. The script model features indicate a threat by a prescriber. The script filler model features indicate a threat by a pharmacy. 
       FIG. 1B  is a block diagram of an example system  100 B, according to an example embodiment. The system  100 B is an example embodiment in which data integration may be performed and used to identify a fraud, waste and abuse variable value, which can be a risk score. The system  100 B includes a data query device  102  in communication with a data manager device  106  over a network  104 . The system  100 B may also include a data analysis device  108 , a benefit manager device  110 , and a data supplier device  112 . The system  100 B further includes a client device  150  that can be loaded with a viewer and can have viewer data that indicates at least of one the variable value, statistical analysis of the variable values (e.g., over time, trends, thresholds, violations of thresholds, billing amounts and the like) and fraud, waste, or abuse status, which may be based on the output from any one of the devices  102 ,  108 , or  110 . 
     The data query device  102  runs a data query, or multiple data queries, on raw data or cleaned data to obtain information of interest (e.g., to a query operator of the data query device  102 ), e.g., a risk score or identification of types of data that influence a risk score as possible FWA. The query operator may be a person that is performing the data query analysis utilizing the data query device  102  for himself or herself, on behalf of an organization with whom the person is employed or otherwise engaged, on behalf of an organization for whom the data query is being provided, pursuant to a device request, or otherwise. The data query device  102  can run statistical analysis of the prescription or medical data in the database to determine a threat model or a risk model, e.g., identifying features or parameters that indicate possible FWA. The features are combined using weights and impact values to compute a risk score. The data query device  102  can determine features that indicate a possible threat, e.g., FWA, from the total of the types of data in the database. The data query device  102  may start at a point in the data at which a known threat, e.g., a known FWA event, has occurred. The preceding data (i.e., a reduced data set) is analyzed to determine the features that indicate the known threat, e.g., a FWA event. The features being a further subset of the database (a reduced subset from the reduced data set that predates the known threat) will allow the ability to analyze the voluminous data that relate to prescription claims or to medical data outside of the reduced data subset. Absent using only the feature set for a specific threat calculation, the variable value representing the threat, e.g., a risk score, cannot be efficiently calculated from the data. 
     The data query device  102  can automatically run instructions to determine a threat variable value, e.g., a fraud, waste and abuse risk score. The data query device  102  can run a threat analysis on a rolling basis, e.g., every first-time period (two weeks or a month) on data spanning a second-time period (e.g., a year or more) using models including the features as determined herein. In some embodiments, the query operator may utilize the data query device  102  to communicate with an analysis operator (e.g., through the data analysis device  108 ). In some embodiments, the data query device  102  may operate automatically (e.g., pursuant to a script, pursuant to a learning algorithm, or otherwise). In an embodiment, the data query device  102  may query the data to determine a threat variable value, e.g., a FWA risk score, at set time periods, e.g., every month or every two weeks. The data query device  102  can also operate on a daily basis or upon instruction at any point in time. 
     Examples of the devices  102 ,  106 ,  108 ,  110 ,  112 , which can be modified to be dedicated to the present system, include dedicated devices that include a processor and memory to store instructions that are loaded into the processor to form a dedicated machine for determining models for threats or using the models to calculate variable threat values. In an example, the devices are mobile. The devices  102 , 106 , 108 , 110 ,  112  may also include other computing devices, such as desktop computing devices, notebook computing devices, netbook computing devices, gaming devices, and the like, which are loaded with specific instructions to develop risk scores as described herein. Other types of dedicated electronic devices may also be used. 
     The network  104  by which one or more than one of the devices  102 ,  106 ,  108 ,  110 , 112  may communicate, may include, by way of example, Mobile Communications (GSM) network, a code division multiple access (CDMA) network, 3rd Generation Partnership Project (3GPP), an Internet Protocol (IP) network, a Wireless Application Protocol (WAP) network, a Wi-Fi network, or an IEEE 802.11 standards network, as well as various combinations thereof. The network  104  may also include optical communications. Other conventional and/or later developed wired and wireless networks may also be used. In some embodiments, the network  104  may include proprietary network communication technologies such as secure socket layers (SSL) technology, technology found in a prescribing network (e.g., the electronic prescribing network operated by Surescripts of Arlington, Va.), and the like. The network  104  can be used to link multiple devices to databases and forward threat variable values or flags of potential FWA to a remote device, e.g., a mobile device over a wireless network. 
     The data manager device  106  manages data that is ultimately queried by the data query device  102 . As part of its operations, the data manager device  106  may clean the data that it manages (e.g., see  FIG. 13  and related description below). In some embodiments, the data manager device  106  may be responsible for advance generation of information (e.g., related to threat risk) provided in response to a query. For example, certain profiles or portions of profiles of prescribers, pharmacies, and patients may be created in advance of a query, which can be part of a FWA risk score query. 
     The data analysis device  108  is a device that analyzes the data received by the data query device  102 . For example, fraud, waste, and abuse analysis may be performed utilizing the data analysis device  108  based on the data received (e.g., from the data query device  102 ). In some embodiments, the fraud, waste, and abuse analysis may include determining fraudulent submission and/or of adjudication of prescription claims by a pharmacy benefit manager (PBM). The fraud, waste, and abuse may be based on improper provider behavior, member/patient behavior, pharmacy behavior, drug supplier behavior, or the like. 
     In an example embodiment, the data analysis device  108  may receive the results of a query conducted by the query device  102 , in which the results may include cleaned data. The data analysis device  108  may analyze the query results including the cleaned data to provide a threat value, e.g., a FWA risk score, and other associated data to determine potential FWA. 
     The benefit manager device  110  and/or the data supplier device  112  may provide data to the data manager  106  for cleaning and, when applicable, for querying, e.g., to determine the FWA threat value and other associated data to determine potential FWA. 
     The benefit manager device  110  is a device operated by an entity at least partially responsible for the management of a drug and/or medical benefit program. While the entity operating the benefit manager device  110  is typically a pharmacy benefits manager (PBM), other entities may operate the benefit manager device  110  either on behalf of themselves, the PBM, or another entity. In some embodiments, the benefit manager that provides the drug benefit may also provide one or more than one additional benefits including a health benefit, a dental benefit, a vision benefit, a wellness benefit, a radiology benefit, a pet care benefit, an insurance benefit, a long-term care benefit, a nursing home benefit, and the like. 
     Some of the operations of the PBM that operates the benefit manager device  110  may include the following. A member (or a person on behalf of the member) attempts to obtain a prescription drug at a retail pharmacy location where the member can obtain drugs in a physical store from a pharmacist or pharmacist technician, or in some instances through mail order drug delivery from a mail order pharmacy location. The prescription drug may otherwise be received through a different delivery channel such as a prescription drug kiosk station. All of this data may be stored and related to the patient, the prescriber and the pharmacy. 
     The member may have a co-pay for the prescription drug that reflects an amount of money that the member is responsible to pay the pharmacy for the prescription drug. The money paid by the member to the pharmacy may come from the personal funds of the member, a health savings account (HSA) of the member or the member&#39;s family, a health reimbursement arrangement (HRA) of the member or the member&#39;s family, a flexible spending accounts (FSA) of the member or the member&#39;s family, or the like. An employer of the member and/or a prescription/health/medical benefit plan may directly or indirectly fund or reimburse the member or an account of the member for the co-pay. In an example, the participation in a FSA may be a factor used to calculate the risk score. 
     The amount of the co-pay paid by the member may vary by the benefit plan of the client with the PBM. The member&#39;s co-pay may be based on be a flat co-pay (e.g., $10), coinsurance (e.g., 10%), and/or a deductible (e.g., for first $500 of annual prescription drug spend) for certain prescription drugs, certain types of prescription drugs, and/or all prescription drugs. 
     In certain instances, the member may not pay the co-pay or may only pay for a portion of a co-pay for a prescription drug. For example, if the usual and customary cost for a generic version of a prescription drug is $4, and the member&#39;s flat co-pay is $20 for the prescription drug, the member may only pay $4 to receive the prescription drug. In another example involving a worker&#39;s compensation claim, no co-pay may be due by the member for the prescription drug. In an example, the amount of co-pay that a patient pays to fill a prescription may be used as a factor in calculating the threat variable value, e.g., a risk score. For example, if the patient is willing to fill a prescription at a pharmacy location that requires a higher co-pay than a lesser amount at another pharmacy location, this may be a factor used in calculating the threat variable value. 
     In conjunction with receiving the co-pay (if any) from the member and dispensing the prescription drug to the member, the pharmacy submits a claim to the PBM for the prescription drug. The PBM may perform certain adjudication operations including verifying the eligibility of the member, reviewing the formulary to determine appropriate co-pay, coinsurance, and deductible for the prescription drug, and performing a drug utilization review (DUR) on the member. The PBM then provides a response to the pharmacy following performance of the aforementioned operations. As part of the adjudication, the client (or the PBM on behalf of the client) ultimately reimburses the pharmacy for filling the prescription drug when the prescription drug was successfully adjudicated. The aforementioned adjudication operations generally occur before the co-pay is received and the prescription drug dispensed. However, the operations may occur simultaneously, substantially simultaneously, or in a different order. In addition, more or less adjudication operations may be performed as part of the adjudication process. The data associated with an adjudication may be used to determine a threat variable value. In some cases, there may be over fifty or one hundred distinct data types that are associated with the adjudication. In some cases, there may be over three hundred data types, including derived data that can be associated with the adjudication. The results from an adjudication operation, including but not limited to any of the distinct data and the derived data, can be used in determining the FWA threat variable value, e.g., for each patient, pharmacy and prescriber. The data sets as a whole may include data that are not indicative or correlated to potential FWA. The data sets can be reduced to only the top five or top ten data types (i.e., a subset) that correlate to potential FWA. 
     The data supplier device  112  is device that has and/or may provide data regarding a single data category, or multiple data categories, of interest to the data manager device  106 . For example, the data supplier device  112  may have data regarding prescribers, pharmaceutical manufacturers, prescription drugs, prescription drug average wholesale price (AWP), co-pays, PBM clients, and the like. In some embodiments, the data may be developed through analysis performed by the data supplier device  112  or by a person or organization that operates the data supplier device  112 . In some embodiments, the data may be developed by a single organization, or multiple organizations, and provided to the data supplier device  112 . The data developed or obtained by the data supplier device  112  need not be related to prescription drugs, but may be from one, or more than one, data categories of interest to the data manager device  106 . In some embodiments, the data supplier operating the data supplier device  112  is a client of the PBM operating the benefit manager device  110  and/or a client of the data manager operating the data manager device  106 . In some embodiments, the data supplier operating the data supplier device  112  is a governmental organization. The data supplier may also provide geographic information related to all patients, pharmacies and prescribers. 
     The system  100  may include a single database, or multiple databases, maintained by respective devices operated by or on behalf one or a number of different persons and/or organizations. The communication may occur directly (e.g., through local storage) and/or through the network  104  (e.g., in a cloud configuration or software-as-a-service) with a device that stores a respective database. 
       FIG. 1  represents an example deployment of the databases  114 ,  116 ,  118  with respective devices  106 ,  110 ,  112  respectively. However, the system  100  is not limited to this configuration. The databases  114 ,  116 ,  118  may be deployed on the data manager device  106 , the data query device  102 , the data analysis device  108 , the benefit manager device  110 , or the data supplier device  112 , on more than one of the devices  102 ,  106 ,  108 ,  110 ,  112 , partially on more than one of the devices  102 ,  106 ,  108 ,  110 ,  112 , or may otherwise be deployed. The deployment may occur on local storage, remote storage, removable storage, and/or a different type of storage associated with the devices  102 ,  106 ,  108 ,  110 ,  112 . Additionally, while a single database is depicted for each of the respective databases  114 ,  116 ,  118  is shown, multiple databases may be implemented. In the case of multiple databases, the different databases may be deployed on different systems, including the devices  102 ,  106 ,  108 ,  110 ,  112  and/or a third-party device or network. 
     The data manager database  114  may store source data  120 , master data  122 , reference data  124 , transformation data  126 , standardization data  128 , and/or derived data  129 . Other data may also be stored within the data manager database  114 . This data relates to claims data, adjudication data and other data for determining threat variable value, e.g., FWA risk score(s). 
     The source data  120  may generally include data to be cleaned and then used as master data  122  in performing claims data processing or FWA processing. The source data  120  may be received from the benefit manager device  110  and/or the data supplier device  112 . Thus, the source data  120  may include member data  130  and/or the claims data  132  stored within the benefit manager database  116 , and/or the data supplier data  138  stored within the data supplier database  118 . Any of this data may be used to determine a threat variable value, e.g., FWA risk scores. 
     In some embodiments, in addition to including the raw unverified and/or correct data (e.g., healthcare professional information, prescription information, member information, pharmacy information, drug information, or the like), the source data  120  may also include the transformation data  126 . 
     In some embodiments, the source data  120  includes the claims data  132 . In some embodiments, the source data  120  links to the claim data  132  (e.g., by linking to the claims data  132  as stored in the database  116 ). This data can be used to determine threat variable values, e.g., FWA risk scores. 
     By way of example, the master data  122  may include data attributes for many healthcare providers (such as healthcare provider name, healthcare provider address, healthcare provider professional affiliations, healthcare provider NPI number, or the like), members (such as member name, member address, member date of birth, member healthcare plan identification number, or the like), drugs (such as drug name, drug NDC, brand name, generic name, therapy class, prescription drug average wholesale price (AWP), or the like.), and pharmacies (such as pharmacy name, pharmacy address, pharmacy NPI number, or the like). The information included in the master data  122  may have been verified, or cross-checked, as being correct and accurate. For example, healthcare provider information in the master data  122  may be verified based on comparisons to information obtained from CMS NPI directories, DEA identification updates, PBM provider databases, practitioner state licenses and sanctions databases, previously submitted pharmacy claims, postal service addresses and geocodes, and the like. The information utilized to verify the master data  122  may be received from, for example, the benefit manager database  116 , the data supplier database  118 , and/or another source. Similarly, pharmacy information in the master data  122  may be verified based on comparisons to information obtained from CMS NPI directories, DEA identification updates, PBM pharmacy databases, practitioner state licenses and sanctions databases, previously submitted pharmacy claims, postal service addresses and geocodes, pharmacy ownership records, and the like. Drug information in the master data  122  may be verified based on comparisons to information obtained from drug product tables, DEA provided information, previously submitted pharmacy claims, and the like. As such, based on the verifications, the information included in the master data  122  may be considered correct and accurate. Accordingly, the information within the master data  122  may be considered clean. The master data  122  may further include dates that are associated with each data record. The time that data is generated or a prescription adjudicated may be used in determining threat variable values, e.g., the FWA risk score. Any of the data may be used to determine threat variable values, such as an FWA risk score. 
     In some embodiments, the master data  122  is in the form of master records. In general, a master record is a collection of data associated with a particular person or entity (e.g., a portion of the master data  122 ). A master record need not be a specific type of file format, record format, or limiting type of data structure as such, but may refer to the related data for the particular person or entity among a collection of data. 
     The source data  120  may include as-is data with the same data elements as the master data  122 , the master data  122  itself, and all verification data including current and historical verified and edited data. Any of these data types may be used to determine threat variable values, an FWA risk score. 
     The reference data  124  may be data associated with master data  122  but that is deemed less significant or valuable. For example, the reference data  124  may include an address that is incorrect or no longer current, while the master data  122  includes an address that is deemed correct and current. The reference data  124  may include erroneous data, data that is out of date, data from a less reliable source relative to the master data  122 , or the like. 
     The transformation data  126  includes data reflecting how to transform or correct the source data  120 . The transformation data  126  may be general, data source specific, or otherwise. The transformational data  126  may be included within the source data  120  and/or the master data  122 , separately stored in the database  114 , or stored as part of a separate data collection, or otherwise. The transformation data  126  can be used to determine threat variable values, e.g., FWA risk scores. 
     For example, the transformation data  126  may define a transformation for correcting the differences between the received data attribute of the source data  120  and the data attribute included within the master data  122 . The degree and/or nature of the defined transformation may vary depending upon preferences and/or rules. For example, the transformation may include a substitution of the last name included in the received source data  120  with the last name included in the master data  122 . Alternatively, the transformation may include a substitution of the “0” in the last name included in the source data  120  with an “i” in the last name included within the master data  122 . 
     The transformation data  126  may include information regarding various transformations that have been made to raw data included within the source data  120  as part of verifying the data and/or correcting the data so that it can be included within the master data  122 . In some embodiments, the transformation data  126  may include transformations that may have been defined as generally described above. For example, the transformation data  126  may include particular transformations that were made to raw data attributes to achieved corrected data attributes that may be included within the master data  122 . 
     The transformation data  126  may identify one, or more than one, transformations that may have been made to previously received data attributes that were different than the data attributed included within the master data  122 . For example, previously received data (e.g., which may also be stored in the source data  120 ) may have included a misspellings of the prescribing healthcare professional&#39;s last name as “Smuth,” “Snith,” “Smoth,” “Smurh,” etc. Corresponding transformation data  126  may include transformations in which the incorrect letter is substituted with the correct letter. Other similar transformation data  126  may be included. 
     The standardization data  128  includes data reflecting standardized formats including a standardized spelling format, a standardized capitalization format, a wording appearance format, a numbering appearance format, and the like. 
     The derived data  129  is data created using the master data  122  directly or as an index (e.g., in to the claims data  132 ) that provides analysis of potential interest. For example, the derived data may include analytical comparative profiles calculated for various healthcare participants. The derived data  129  can be threat variable values, such as FWA risk scores, over time or other computed data that can be used to alert the system  100  to potential fraud, waste or abuse. Examples of derived data include, but are not limited to, score thresholds, number of audit discrepancies, increase in activity of dollars billed or adjudicated, numbers of claims adjudicated, drug wholesaler data per pharmacy, and the like. 
     In some embodiments, the database  114  may include drug data. The drug data may include drug name (e.g., technical name and/or common name), other names by which the drug is known by, active ingredients, an image of the drug (e.g., in pill form), and the like. The drug data may include information associated with a single medication or multiple medications. In some embodiments, the drug data may be stored as a portion of the source data  120 . The drug data may be used to determine threat variable values, e.g., FWA risk scores. The drug data may also include flags that indicate that a particular drug may be more prone to fraud, waste or abuse than another drug. Examples of drug classes that may be more prone to FWA include, but are not limited to narcotics, opioids and benzodiazepines. 
     In some embodiments, the database  114  may include provider data. The provider data may include information regarding prescribers and/or providers of healthcare services. The provider data may include, by way of example, provider name, national provider identifier (NPI) information associated with the providers, location data regarding the location of the providers, information data regarding the provider hours and/or telephone number, provider network association data defining the provider network associations of which the providers are associated, business relations with other providers, services provided by the provider (e.g., prescriptions issued by the provider, treatment services administered by the provider, testing services administered by the provider, etc.), and the like. The providers may be at a physician&#39;s office, a hospital, a testing laboratory, a pharmacy, a location associated with a PBM, or the like. In some embodiments, the provider data may be stored as a portion of the source data  120 . The provider data may be used to determine threat variable values, e.g., FWA risk scores. 
     In some embodiments, the drug data and/or the provider data may be received from a device (e.g., the benefit manager device  110  from the benefit manager database  116 ). In some embodiments, the drug data and/or the provider data may be derived from the source data  120 . In some embodiments, the drug data and/or provider data are a portion of the master data  122 . 
     The benefit manager device  110  may provide certain member data  130 , claims data  132 , prescription data  134 , and/or pharmacy data  136  from the database  116  for storage in the database  114  as part of the source data  120 . The member data  130  may include information regarding members of a pharmacy benefit plan and/or patients of one, or more than one, pharmacy. The member population may be for a single pharmacy benefit plan (e.g., offered on behalf of a single company), or may for multiple pharmacy benefit plans. In general, the member data  130  may include member name, member contact information (e.g., address, telephone number, email address, and the like), and a client identifier that identifies the client associated with the member and/or a member identifier that identifies the member to the client. The member data  130  may be used to determine threat variable values, e.g., FWA risk scores. 
     The claims data  132  includes information regarding pharmacy claims adjudicated by the PBM under a drug benefit program provided by the PBM for one, or more than one, clients. In general, the claims data  132  may include client data (e.g., including an identification of the client that sponsors the drug benefit program under which the claim is made, company name, company address, contact name, contact telephone number, contact email address, and the like), an identification of the member that purchased the prescription drug giving rise to the claim, the prescription drug that was filled by the pharmacy (e.g., the national drug code number), the dispensing date, generic indicator, GPI number, medication class, the cost of the prescription drug provided under the drug benefit program, the copay/coinsurance amount, rebate information, and/or member eligibility. The claims data  132  may also include claims adjudicated for healthcare related services other than prescriptions filled under a drug benefit program. Examples of other healthcare related services may include medical services (such as treatment, screening services, laboratory services, et al.), dental related services, and vision care related services. Additional information may be included in the various claims of the claims data  132 . The claims data  132  may be used to determine threat variable values, e.g., FWA risk scores. 
     The prescription data  134  may include information regarding prescriptions that may be issued by providers on behalf of patients, who may be members of the drug benefit plan, for example to be filled by a pharmacy. Examples of the prescription data  134  include patient names, medication or treatment (such as lab tests), dosing information, and the like. The prescriptions may be electronic prescriptions, paper prescriptions that have been scanned, or otherwise. In some embodiments, the dosing information reflects a frequency of use (e.g., once a day, twice a day, before each meal, etc.) and a duration of use (e.g., a few days, a week, a few weeks, a month, etc.). The prescription data  134  may be used to determine threat variable value, e.g., FWA risk scores. 
     The pharmacy data  136  may include information regarding pharmacies. The pharmacy data may include, by way of example, national provider identifier information associated with the pharmacies, location data regarding the location of the pharmacies, information data regarding the pharmacy hours and/or telephone number, pharmacy network association data defining the pharmacy network associations of which the pharmacies are associated, and the like. The pharmacy data  136  may be used to determine threat variable values, e.g., FWA risk scores. 
     The data supplier data  138  as may be stored in the database  118  may include the member data  130 , the claims data  132 , clinical data, provider data, drug data, the prescription data  134 , and/or the pharmacy data  136 . The member data  130  and the claims data  132  may be for a same member population as maintained by the benefit manager operating the benefit manager device  110 , or for a different population. In some embodiments, the source data  120  is stored separately from the member data  130 , claims data  132 , and/or data supplier data  138 . The data supplier data  130  may be used to determine threat variable values, e.g., FWA risk scores. 
     The clinical data may include clinical records regarding member diagnosis and/or therapy. The clinical data may be obtained from hospitals, medical insurance companies, drug trials, medical laboratories in the form of clinical records and/or the member via online questionnaires, for example. In some embodiments, the clinical data includes medical claims and/or lab data. In some embodiments, the clinical data includes medication data (e.g., for a claim made under the medical benefit instead of the prescription drug benefit). The clinical data may be used to determine threat variable values, e.g., FWA risk scores. 
     By way of example, a member of a healthcare benefit program, such as a drug benefit program, may request a drug prescription be filled by a pharmacy, such as a retail pharmacy or a mail order pharmacy. When the member requests that the drug prescription be filled by the pharmacy, the pharmacy may submit a drug prescription claim, to the benefit manager of the healthcare benefit program (such as the drug benefit program as operated by a PBM). The prescription drug claim may be submitted to the PBM for adjudication to determine eligibility of the member for coverage of the prescription under the drug benefit program, a required co-pay to be paid by the member, a reimbursement to the pharmacy, etc. The data associated with the prescription drug claim may be stored in one, or more than one, of the member data  130 , and the claims data  132 . In some embodiments, receiving the data may include accessing the member data  130  and/or the claims data  132  stored within benefit manager database  116 . 
     By way of example, a prescription drug claim may, for example, identify the member requesting the fill of the drug prescription, the pharmacy at which the request to fill the drug was made, a drug benefit plan identifier, an identification of the drug to be filled, and an identification of the prescribing healthcare provider, such as a doctor or other prescriber. The member may be identified by one or more of a member name, member identification (e.g., an identification number use to identify the member with respect to the drug benefit program), a member address, a date of birth, as well as other information. Similarly, the pharmacy may be identified by a pharmacy name, an address, a national provider identifier (NPI) number, etc. The drug to be filled (or that has been filled) may be identified by one or more of a drug name, a brand name, a generic name, a therapy class, a national drug code, a dosage, a form of the drug, or other information. The prescribing healthcare professional may be identified by, for example, name, addresses, professional affiliation (e.g., a healthcare provider organization, such as a medical practice), an NPI number, DEA number, or other identifying information. Each piece of information (e.g., member name, member date of birth, pharmacy NPI number, pharmacy address, drug name, drug NDC, prescriber NPI number, prescriber name, etc.) may each be an attribute of the claims data  132  for a particular prescription drug claim. This claim data may be used in adjudication of the claim and in determination of threat variable values, e.g., FWA risk scores. 
     As generally described above, a device operator of the data query device  102  may utilize the data query device  102  to run a data query, or multiple data queries, on the cleaned master data  122  to obtain information of interest (e.g., to the device operator of the query device  102  or to another individual or device). Further, a device operator of the data analysis device  108  may perform a data analysis of the query results of the query run on the data query device  102 , which includes cleaned master data  122 . The query run may be determined by a risk model. The query results may include threat variable values, e.g., risk scores. The threat variable values can be for individuals (e.g., patients), script originators (e.g., prescribers) and script fillers (e.g., pharmacies). The device operator of the data analysis device  108  may perform the data analysis for himself, on behalf of an organization with which the device operator is employed, or on behalf of an organization for whom the data analysis is being provided. In some embodiments, the device operator of the data query device  102  and the device operator of the data analysis device  108  may be the same person, or may be different people. 
     Further, in some embodiments, the device operator of the data query device  102  and the device operator of the data analysis device  108  may be employed by the same organization and/or may act on behalf of the same person or the same organization. In an example, the device  102  is at a client, e.g., a business providing a pharmacy benefit or a governmental organization, e.g., the Department of Defense. The device  102  may query the databases through an interface similar to that described in U.S. patent application Ser. No. 14/484,176, titled SYSTEMS AND METHODS FOR INTEGRATING DATA, assigned to the present assignee, which is hereby incorporated by reference for any purpose. However, if the disclosure being incorporated by reference conflicts with the present written disclosure, the present written disclosure controls interpretation. 
     Various different types of data analysis may be performed by the data analysis device  108  on cleaned master data  122  received by the data query device  102 . For example, fraud, waste, and abuse analysis, cost verification, member verification, provider investigation, drug utilization and the like may be performed utilizing the data analysis device  108  based on the cleaned data received by the data analysis device  108 . 
     While the system  100  in  FIG. 1  is shown to include single devices  102 ,  106 ,  108 ,  110 ,  112 , multiple devices may be used. The devices  102 ,  106 ,  108 ,  110 ,  112  may be the same type of device or may be different device types. When multiple devices are present, the multiple devices may be of the same device type or may be a different device types. Functionality of some or all of the devices  102 ,  106 ,  108 ,  110 ,  112  may be combined into a lesser number of devices, or may be spread among a greater number of devices. For example, the functionality of devices  102 ,  106 ,  108 , 110 ,  112  may be combined into a single device. 
     Moreover, system  100  shows a single network  104 , however, multiple networks can be used. The multiple networks may communicate in series with each other to link the devices  102 ,  106 ,  108 ,  110 ,  112  or in parallel to link the devices  102 ,  106 ,  108 ,  110 ,  112 . 
     The devices  102 ,  106 ,  108 ,  110 ,  112  may be in a client-server relationship with one another, a peer-to-peer relationship with one another, in a different type of relationship with one another, or in a combination of different types of relationships with one another. 
     The person(s) and/or organization(s) operating the devices  102 ,  106 ,  108 ,  110 ,  112  may be the same person or organization, or may be operated by different persons or organizations. 
     By way of example, a pharmacy benefit manager operating the benefit manager device  110  may operate the data manager device  106 . A licensee of the benefit manager may utilize the data query device  102  to perform data queries against the master data  122  maintained in the data manager database  114  by the data manager device  106 . The licensee may use the results of the query in its operation of the data analysis device  108 . 
     The data manager database  114  may include a viewer source  141  and viewer data  142 . The viewer source  141  may include an application that can be used to display viewer data  142  on a remote device (e.g., client device  150 ) that is in communication with the devices  102 ,  106 ,  108 ,  110 ,  112 . The viewer data  142  may include data derived for display on a viewer. The viewer data  142  may also include permissions and the types of data that a viewer may access from the database. The data manager database  114  may store the risk scores  143 . The risk scores data  143  may include three types of data related to risk scoring—risk score models, risk score features, and actual computed risk scores. The risk score models are learned models, which can include statistical analysis, machine learning, and the like, from the data in the data manager database  114  that include subsets of types of data, e.g., features, that can be used to calculate a likelihood of FWA. The computed risk scores are outputs from the risk score models using the features on the prescription or medical data to produce a FWA risk score. The FWA risk score can be one of three categories of risk scores, e.g., a patient risk score, a prescriber risk score, and/or a pharmacy risk score. The risk scores can be threat variable values as described herein 
     The data query device  102  may determine a likelihood of FWA as described herein and transmit a potential FWA warning to a client device  150 . The FWA warning can be based on the computed risk score from the derived risk score models. The client device  150  may be at a client computing system. The client device  150  may receive an input requesting that the PBM investigate the potential FWA that was flagged and transmit the investigation command back to the PBM through the device  102  and the network  104 . The client device  150  may further include a viewer  151  that can act on viewer data  152  received over the network  104  to display a flag for potential FWA and a FWA score or scores. The viewer data  152  may be reformatted data from the data manager database  114 . The FWA risk scores can be threat variable values 
     The model database  160  stores various models that are used to determine threat variable values, e.g., risk scores. The models  160  can be derived to refined based on historical data. The devices  102 ,  106 ,  108 ,  110 ,  112  can load the models and, using the models, determine threat variable values, e.g., risk scores. The threat variable values can then be stored in the risk scores data on database  114 . 
     The model database can include models from the data in the databases  114 ,  116  that can produce predictive FWA risk scores. In an example embodiment, the data query device  102  can request the application of a risk score model to apply to the data in the databases  114 ,  116 . The data analysis device  108  can apply the model in some examples. The device  108  can obtain comparison data relevant to prescription drug claims, medical claims, or both the prescription drug claims and the medical claims provided by the plurality of various data sources, as described herein. The plurality of various data sources can include at least one of a benefit manager database, a data supplier database, a data manager database, and a pharmacy database. and the plurality of various data sources deployed on respective devices, the data manager database configured for storing source data received from at least one of a plurality of various data sources, a master record, and reference data record. The reference data record includes a plurality of data attributes that are associated with the plurality of verified data attributes of the master record. The plurality of data attributes of the references data record are not deemed most significant or valuable. In response to a determination that there is a difference and that the relative level of source priority of the data source of the comparison data is equal to or greater than the data source of the current state version of the master record, storing the current state version of the master record in the reference data recorder and in response to a determination that there is a difference and that the source significance of the data source of the comparison data is less than the data source of the current state version of the priority of the data source of the comparison data is equal to or greater than the data source of the master record, storing the comparison data in the reference data record. The present risk score model can be derived from the master record. The risk score models can be applied to the master record data to compute a risk score. 
       FIG. 2  illustrates the data query device  102 , according to an example embodiment. The data query device  102  may include a risk score subsystem  202 . The risk score subsystem  202  may access a particular risk score model. The risk score subsystem may use a risk score model that uses features identified as related to FWA activities in the prescription drug system or medical care system. The FWA activity can be by the patient, the prescriber, the pharmacy, or combinations thereof. The risk score subsystem  202  can be directed to one of the patient risk score, the prescriber risk score, or the pharmacy risk score. The risk score subsystem  202  may determine of FWA risk using the data stored in the databases, e.g., claim adjudication data and related data in the PBM system using the model. The data query device  102  may be deployed in the system  100 , or may otherwise be used. 
       FIG. 3  illustrates the data manager device  106 , according to an example embodiment. The data manager device  106  may include a risk score subsystem  202 . The risk score subsystem  202  may access a particular risk score model. The risk score subsystem may use a risk score model that uses features identified as related to FWA activities in the prescription drug system or medical care system. The FWA activity can be by the patient, the prescriber, the pharmacy, or combinations thereof. The risk score subsystem  202  can be directed to one of the patient risk score, the prescriber risk score, or the pharmacy risk score. The risk score subsystem  202  may determine of FWA risk using the data stored in the databases, e.g., claim adjudication data and related data in the PBM system. The data manager device  106  may be deployed in the system  100 , or may otherwise be used. 
     By way of example, the risk score subsystem  202  may be deployed in the data query device  102 , the data manager device  106 , or both the data query device  102  and the data manager device  106 . In some embodiments, the risk score subsystem  202  may provide server-side functionality for the data query device  102 . The data query device  102  may then perform some of the functionality while other functionality is performed by the data manager device  106 . The risk score subsystem  202 , in an example embodiment, is a dedicated processor loaded with instructions to apply the one of the patient risk score model, the prescriber risk score model or the pharmacy risk score model that is of interest. The risk score subsystem uses the features in the model to access, weight and combine the weighted values into a score, e.g., a single numerical value of FWA risk. The numerical score may be provided as a raw number that a system uses to flag potential FWA or provided as a raw number for comparison to other FWA score results. The risk score can also be normalized, e.g., in a range, percent or the like, so that the risk score output to a viewer is easily compared to current risk score calculations, e.g., at a viewer  151 . 
       FIG. 4  illustrates the data analysis device  108 , according to an example embodiment. The data analysis device  108  may be used by a device operator to enable risk score analysis. The data analysis device  108  may be deployed in the system  100 , or may otherwise be used. The data analysis device  108  may include the risk score subsystem  202 , which can access and apply the risk score models to data, e.g., adjudication data. The risk score subsystem  202  may include the features as described herein with relation to other figures. 
       FIG. 5  illustrates the benefit manager device  110 , according to an example embodiment. The benefit manager device  110  may be used by a device operator to enable risk score analysis. The benefit manager device  110  may be deployed in the system  100 , or may otherwise be used. The benefit manager device  110  may include the risk score subsystem  202 , which can access and apply the risk score models to data, e.g., adjudication data. The risk score subsystem  202  may include the features as described herein with relation to other figures. 
       FIG. 6  illustrates the model database  160 , which can include a plurality of different models that can be used to determine FWA risk scores. The model database  160  includes at least one patient model  601  that can be used to determine a patient risk score for individual patients that are part of the database, e.g., each patient that has an adjudicated claim in the database. There may be tens of millions of patient risk scores, e.g., greater than sixty million patients. The model database  160  includes at least one prescriber model  603  that can be used to determine a prescriber risk score for individual prescribers that are part of the database, e.g., each prescriber that is associated with at least one adjudicated claim in the database. There may be over one million prescriber risk scores. The model database  160  includes at least one pharmacy model  605  that can be used to determine a pharmacy risk score for an individual pharmacy that are part of the database, e.g., each pharmacy that is associated with an adjudicated claim in the database. There may be tens of thousands of pharmacy risk scores, e.g., greater than twenty thousand pharmacy risk scores. The models  601 ,  603 ,  605  include features that are indicative of and can be used to compute a likelihood of FWA. The models  601 ,  603 ,  605  can have some of the same features and may have different features. The features can be individually weighted and used as influencing the risk score to a different level. The models are also not entirely dependent on actual claims adjudicated data. The models can use derived features from the database. The models can also be use ancillary data. Ancillary data is data that is not actual claims adjudication data but is stored in the database and can be related to a likelihood of FWA. Examples of ancillary data can include the number of times that a particular pharmacy has pinged the adjudication system, the number of times that a particular pharmacy has pinged the adjudication system for a known drug that has an increased likelihood for FWA. Opioids and other narcotics can be considered as drugs that have a greater likelihood for FWA. Other ancillary data can include a patient receiving or attempting to refill prescriptions at multiple pharmacies or receiving prescriptions from multiple doctors. The models are derived from known cases of FWA and working backwards in time in the database, the features (e.g., types in the database) that indicate possible FWA are determined. These features are a reduced subset of the types of data in the database. The model database  160  stores specific predictive models that are developed from the data stored in the databases. These predictive models operate to reduce the data types, and hence the total data, that is reviewed to produce a risk score for possible fraud, waste or abuse. The reduction of the data types that are involved in the model makes the computing device applying the model operate more efficiently by focusing the computer on a reduced number of data types and a reduced amount of data. The predictive risk model references only those data types that a predictive of possible fraud, waste and abuse. 
       FIG. 7  illustrates examples of models that can be used in the devices described herein to calculate risk scores that can be used to identify various forms of fraud, waste or abuse (FWA). These models and risk scores can be stored in the benefit manager database  116 . The commercial pharmacy model  701  uses the adjudication data to produce a commercial pharmacy risk score  702  for each commercial pharmacy that has an adjudication of a pharmacy claim in the database. The commercial pharmacy risk score  702  represents the likelihood that any particular pharmacy is committing FWA. The Department of Defense model  703  uses the adjudication data to produce a Department of Defense pharmacy risk score(s)  704  for each pharmacy that fills prescription in the Department of Defense health program. Other government programs may use the Department of Defense model to determine FWA risk score(s). The Department of Defense risk score  704  represents the likelihood that any particular pharmacy fulfilling prescriptions for the Department of Defense is committing FWA. The prescriber model  705  uses the adjudication data to produce a prescriber risk score  706 . The prescriber risk score  706  represents the likelihood that any particular prescriber is committing FWA. The patient model  707  uses the adjudication data to produce a patient risk score  708 . The patient risk score  708  represents the likelihood that any particular patient is committing FWA. The pharmacy segmentation model  709  uses the adjudication data to produce a pharmacy segmentation model risk score  710 . The pharmacy segmentation risk score  710  represents the likelihood that any particular pharmacy in a pharmacy segment is committing FWA. A pharmacy segment can be based on any relatable factor that is the same in at least two pharmacies, e.g., a chain pharmacy, a compounding pharmacy, independent pharmacy, location, population size served by the pharmacy and the like. The pharmacy segmentation model  709  uses the adjudication data to produce a pharmacy segmentation score  710 . The pharmacy segmentation score  710  represents the behavioral business segment into which any particular pharmacy falls. Segments were developed via unsupervised learning, clustering procedures and represent how a pharmacy behaves in their Rx dispensing as opposed to how they contract with the pharmacy benefit manager. A pharmacy segment can be based on any relatable factor that is the same in at least two or more pharmacies, e.g., a chain pharmacy, a compounding pharmacy, independent pharmacy, location, population size served by the pharmacy and the like 
       FIG. 8  illustrates a schematic view  800  of methodology to determine a risk score  801 . The risk score  801  can be formed of various components, which can be stored in the databases described herein and determined using the devices described herein. The components can also be fed into a statistical analyzer (e.g., a risk model) in the devices. The statistical analyzer may include a logistic regression module to compute the risk score. The risk score can be generated from other supervised, classification model. The output of a risk score can be a one or true for the entity classifies as a fraud or a zero or false for the entity that classifies as a non-fraud. A drug hotlist component  803  is a list of drugs that are more likely to be involved in FWA. The drug hotlist component  803  could be a proprietary list of drugs that are commonly, falsely billed based on past false billings as determined by the system described herein. An example of a drug hotlist component  803  can include, but is not limited to, opioids and benzodiazepines. The drug hotlist component  803  will list drugs by their generic names and brand names and drug identification numbers. 
     An adjudication days component  805  can include the average number of days to adjudicate a prescription claim. This component can be the calculation of the number of days between the service date, e.g., the date the drug is sold or the date of sale and when the drug claim is processed through the billing system at the PBM correctly. The longer the adjudication day component, the more likely the pharmacy may be involved in FWA. 
     An average hotlist component  807  can include the number of prescriptions on the hotlist per member that are greater than a days-supplied threshold and greater than a number of claims. In an example, the days supplied threshold is twenty-five days. In an example, the number of claims is also twenty-five. 
     A prescriber hotlist component  809  can include a percentage of hotlists over a prescriber at a particular pharmacy. This component can indicate possible FWA when a particular prescriber prescribes a high number of hot listed drugs compared to other prescriptions that particular prescriber has at an individual pharmacy. 
     A controlled substance component  811  can include a rate at which a pharmacy fills certain controlled substances in its prescriptions or when a patient receives prescriptions for certain controlled substances at a pharmacy. 
     A compound drug rate  813  can include a percentage of dollars that come from compounded drugs relative to non-compounded drugs. The dollar amount related to compounded drugs or the number of compounded drugs, then there is a higher risk of FWA. 
     A whole number billing component  815  can include the number of times a particular pharmacy bills in a whole numbers, e.g., no cents, such as $9.00, $20.00 or $40.00. The higher the number of whole number billings, then there is an increased FWA risk. 
     A benzo script component  817  can include the number of benzodiazepines prescriptions being filled at a particular pharmacy or by a particular patient. The benzo script component  817  can be an average number of benzo scripts per member at that pharmacy. The higher the number, then it is more likely that there is FWA. 
     A related controlled pain prescription component  819  can include a pharmacy&#39;s number of pain control prescriptions versus other pharmacies in a similar geographic area. In an example, in a pharmacy&#39;s zip code, and the present system calculates how many controlled pain prescriptions are being filled at the pharmacy relative to other pharmacies in the area, e.g., same zip code, within a certain distance and the like. In an example, the component  819  is a percent calculated by dividing many controlled pain prescriptions are being filled at the pharmacy by the total number in the zip code. The related controlled pain prescription component  819  can be a percent of the number of controlled substances in the zip code on the pharmacy level for a particular pharmacy. 
     The components  803 - 819  represent a reduced number of data types that are being used to predict possible FWA. The components  803 - 819  can represent less than half, less than a third, or less than a tenth of the possible components (or data types) available in the database of prescription data or medical data. The models use these components as they have been proven to be causally linked to possible FWA. Any one of the components may not indicate FWA, but the combination of the components results in a more accurate computed risk score that is an accurate indicator of FWA. 
     The components  803 - 819  can be combined to provide the risk score  801 , which may be a likelihood of FWA for a particular pharmacy. This can be computed on a rolling basis over a set period of time, e.g., one year&#39;s worth of claims data and computed on a weekly basis using a risk score model. The data used in the components  803 - 819  can be adjudication data stored in the databases of the PBM. 
     Other components may be used to determine a risk score for potential FWA. A specialty compound component may be used to determine a risk score. A mail order versus retail component may be used to determine a risk score. Therapeutic categories may be used to determine a risk score. 
     Not all of the components described herein are required for each of the risk scores. These components can be used as features used in calculating risk scores. Patient risk score calculation may use different components that prescriber risk score calculation. Prescriber risk score calculation may use different components that pharmacy risk score calculation. Pharmacy risk score calculation may use different components that patient risk score calculation. However, there may be some overlap in the components between the different risk score types. In various examples, the patient risk score calculation may use different components than the prescriber risk score calculation. The models on which the pharmacy risk score, the patient risk score and the prescriber risk score can be independent of one another in score calculation but can be used in combination to find situations of collusion among one or more entities from the patient, prescriber and pharmacy involved in prescriptions. 
       FIG. 9  shows a schematic view of a system  900  for determining a fraud, waste or abuse risk score. As used herein, a fraud score may reflect fraud, waste or abuse related to a prescription drug, e.g., based on data related to filling or adjudicating the prescription claim. A predictive modeler  901  interacts with an entity fraud case history  903  and a claims database  905  to produce the FWA model that is generated at  907 . The entity fraud model generation  907  uses component sets for each entity type, respectively. The entity types may include a pharmacy, a prescriber and a patient. The generation of the model can start a case of known FWA and work backwards in time on all of the data in the prescription or medical database to determine the types of data that indicate a likelihood of FWA. This types of data are features used in generating the model. The model is composed of features that can be weighted so that some features have a greater influence on any resulting risk score. The model also determines how the features, before or after weighting, are combined. In an example, the features are given a numerical value, then multiplied by a weighting factor, and then combined to output a risk score for the model. as 
     At  909 , the fraud model scores the current data, which can be the past year of data on a rolling basis. The risk scores are produced as provided to a special investigations unit at  910 , which can be a device that filters the results to make a determination for no referral  911  or a client referral  912 . The client referral  912  results from an indication that FWA is likely based on the results from the predictive model. 
     The predictive modeler  901  can use a logistic regression model that can be self-learning to generate an FWA model. Other statistical techniques can be used to produce the model. In an example, the predictive modeler can be a neural network. The model build and verification is performed to determine what variables available in the database (e.g., data types) were actually significant in predicting FWA. The model generation can be fed known FWA entities and some non-FWA entities to train the model. FWA entities are those that are known to have committed FWA at appoint in time. The modeler looks backwards in time, e.g., a year, at all the data to determine which data types are indicative of FWA. The data can be related to the prescription that were filled by a known instance of FWA by a pharmacy, a prescriber, or a patient. The data types that are indicative of FWA are used as features in the model. In an example, the rate of FWA is generally known and data is fed to the model at a rate equal to the known rate across all of the entities. Once the model is trained and verified with the known data, the model can operate on the entire dataset of claims for the time period, e.g., a past month, past quarter, past year or multiple years. In an example, with a trained and verified model, the model can be applied to a new, current, or continuously streaming dataset of prescription claims over a given time period to predict future FWA. The model can be trained and verified with the known data that includes some FWA and some data that is not involved in FWA. The generation of a known working model is necessary to achieve reasonable results as the claims database can includes more than 70,000 pharmacies, 1.6 million prescribers, and about 65 million patients. The model FWA model scores all entities, e.g., the pharmacies, the prescribers, and the patients, to provide a baseline that allows the risk trends to be monitored. 
       FIG. 10A  illustrates schematic view of a predictive fraud model  1000  that can provide an alert within the system of potential fraud. The risk score  1001  for an entity, e.g., a pharmacy, a prescriber, or a patient, (ordinate) is tracked over a time period (abscissa). A threshold  1002  is set. When the risk score meets or exceeds the threshold, the system triggers a review by flagging this entity in the system and transmitting this information to a further device for review. 
       FIG. 10B  illustrates schematic view of a predictive fraud model  1010 , which can provide an alert within the system of potential fraud. The risk score  1011  for an entity, e.g., a pharmacy, a prescriber, or a patient, (ordinate) is tracked over a time period (abscissa). This fraud predictive model alert is triggered when any entity displays a rate of change of greater than a threshold rate over a certain time period (e.g., month to month, quarter to quarter, six months, or other time period greater than one week). The rate of change can be computed as a percentage, e.g., using (score (t A )−score (t B ))/score (t A ), i.e., the new score minus the old score all divided by the old score. The calculated rate of change can be compared to a rate of change threshold. If the rate of change threshold is exceeded or met, then FWA may be indicated. In an example, the rate of change threshold can be set at 50%. In an example, the rate of change threshold can be set at 60%. In an example, the rate of change threshold can be set at 70%. In an example, the rate of change threshold can be set at 75% or higher in increments of 2 up to 99%. This model  1010  captures those behavior changes by the entity before the changes or rate of change reaches the threshold alert in  FIG. 10A  above. The model  1010  alert may indicate more of a behavior changing event in that entity. A behavioral change for a member or patient may include traumatic accident or a new illness. A behavioral change for a prescriber may include joining a new, large benefit network. A behavioral change for a pharmacy may include a nearby pharmacy closing and all Rx&#39;s and patients shift to this pharmacy. These may be legitimate changes that are reflected in the rate of change in an entity over the time period or may indicate the start of fraud, waste or abuse of the prescription system. 
       FIG. 10C  illustrates schematic view of a predictive fraud model  1020 . Like the above examples in  FIGS. 10A and 10B , the risk score  1021  for an entity, e.g., a pharmacy, a prescriber, or a patient, (first, left ordinate) is tracked over a time period (abscissa). A number of audit discrepancies  1022  is tracked over the same time period and is graphed versus the second, right ordinate. The predictive fraud model  1020  would trigger an alert when the risk score  1021  is increasing with an increasing number of audit discrepancies  1022  for that entity over time. This data can be input from a fraud waste and abuse audit group device. Audited claims can be claims which have been billed incorrectly. Billing errors by themselves are not indicative of fraud. However, if there are enough of them, they are indicative of a disregard for appropriate billing. Overlaying audit results with an increasing fraud likelihood score provides an indication of potential fraud, waste or abuse within the PBM network. 
       FIG. 10D  illustrates schematic view of a predictive fraud model  1030 . Like the above examples in  FIGS. 10A-10C , the risk score  1031  for an entity, e.g., a pharmacy, a prescriber, or a patient, (ordinate) is tracked over a time period (abscissa). A prescription cost  1032  is tracked over the same time period and is graphed versus the second, right ordinate. The predictive fraud model  1030  would trigger an alert when the risk score trigger as a post-intervention model review, which is mainly focused on pharmacy or prescriber fraud. An investigation is started at  1033 . The PBM engages the pharmacy network and the various related entities, the models allow us to measure the impacts those engagements have on the entity&#39;s behavior. Ideally, the entity would be educated as to the issue of concern and the model would show a pre/post-intervention decrease in risk score and prescription costs would decrease on that entity. However, if the engagement causes a decrease in risk score (line  1031 ) but an increase in prescription costs (line  1032 ), that would indicate that the entity has changed their behavior but has altered their behavior in a way possibly to go undetected while still increasing their billing. A trigger may be issued at any of  1033 ,  1034 ,  1035  thresholds. 
       FIG. 10E  illustrates schematic view of a predictive fraud model  1040 . Like the above examples in  FIGS. 10A-10D , the risk score  1041  for an entity, e.g., a pharmacy, a prescriber, or a patient, (ordinate) is tracked over a time period (abscissa). A number of claims  1042  is tracked over the same time period and is graphed versus the second, right ordinate. The predictive fraud model  1040  would trigger an alert based on a sharply increasing risk score and an increase in the number of adjudicated claims over time. An entity in the PBM network should behave relatively stable in a risk score over time with some fluctuations. Additionally, a new entity to the PBM network may show an increase initially but would level out and reach some sort of relative equilibrium in score. Conversely, a fraudulent entity would not level out and would increase in risk score and claims volume as a result of the diversion (member), kick-back prescription writing (prescriber), or false billing (pharmacy) increases, which are all types of fraud. 
       FIG. 11  illustrates a method  1100  for purchase verification of adjudicated claims, according to an example embodiment. The method  1100  may be performed by the data query device(s)  102 , partially by the data manager device  106  and partially by the benefit manager device  110 , or may be otherwise implemented. This method inputs data into the database. The data types of this data are used to generate the risk score model(s). 
     At block  1102 , a pharmacy is selected for review based on its adjudication data. As discussed above, a pharmacy which submits higher than expected numbers of claims involving expensive drugs, high demand drugs, low reversal rates, etc. may be selected for review. 
     At block  1104 , the drug sale data from the pharmacy&#39;s wholesaler is accessed, along with the claims that were submitted by the pharmacy device to the PBM devices for adjudication. The data from the pharmacy&#39;s wholesaler may have been received in the form of invoices, electronically via spreadsheet, or in another form. The data regarding claims submitted by the pharmacy to the PBM for adjudication may be stored in an accessible database by the PBM. This data can be used as part of a training data set or used to calculate a pharmacy score, a prescriber score or a patient score. 
     At block  1106 , data regarding the number of units of a prescription drug is determined based on the drug sale data and the adjudicated claims, and in some embodiments, is harmonized. The data regarding the number of units of a prescription drug may be determined based on and/or extracted from the drug sale data and adjudicated pharmacy claims data. Harmonization of the various data regarding the number of units of a prescription drug may also be performed, considering the varying reporting conventions. Such harmonization creates a direct, one-to-one, drug-for-drug, pill-for-pill, dose-for-dose comparison between drugs purchased by the pharmacy and drug claims reimbursed by the PBM. This data can be used as part of a training data set or used to calculate a pharmacy score, a prescriber score or a patient score. 
     At block  1108 , the number of units of a prescription drug in the adjudicated claims is compared with the number of units of a prescription drug sold by the wholesaler. As the number of units of a prescription drug from the adjudicated claims represents the number, type, dose, etc. of the drugs reportedly dispensed by the pharmacy, while the number of units of a prescription drug sold by the wholesalers represents the number, type, dose, etc. of the drugs sold to the pharmacy, a comparison of such data can detect that a pharmacy submitted a claim (and received a reimbursement) for a drug which it never purchased. Thus, at block  1110 , discrepancies are detected and noted as possible fraud. The discrepancy data from block  1110  can be used as an input to determining the risk score. 
       FIG. 12  illustrates a method  1200  for investigating possible fraud, according to an example embodiment. The method  1200  may be performed by the data query device(s)  102 , partially by the data manager device  106  and partially by the benefit manager device  110 , or may be otherwise implemented. The method  1200  may be triggered by a risk score that violates any of the rules or thresholds as described herein. The violation may be transmitted to a remote device at which a decision can be made to further investigate the patient, pharmacy or prescriber that is associated with the FWA violation as determined by the risk score. 
     At block  1202 , where a possible fraud, waste or abuse has been detected, a request is transmitted to the pharmacy device for clarification as to the seemingly fraudulent activity. The pharmacy may be asked to explain the detected discrepancies, and/or provide additional data to support the claims it submitted. 
     At block  1204 , a determination is made as to whether to transmit an additional information request to an associated physician. Such a physician may be able to confirm whether an adjudicated claim is legitimate, or was contrived by the pharmacy and/or patient. Where such a transmission is to be made, at block  1206 , the request for verification is transmitted to the physician (or physician device). 
     Similarly, at block  1208 , a determination is made as to whether to transmit an additional information request to an associated patient. Such a patient may be able to confirm whether an adjudicated claim is legitimate, or was contrived by the pharmacy and/or physician. Where such a transmission is to be made, at block  1210 , the request for verification is transmitted to the patient device. 
     At block  1212 , responses are received, and a determination is made as to whether the responses clarify the circumstances of the possible fraud as being legitimate. This step may be manual or computerized. Where a pharmacy provides additional wholesaler from which it bought drugs, any such additional drug purchases may be investigated via the purchase verification method above. 
     At block  1214 , where a possible fraud has been detected and has not been ruled out, a bill is generated and transmitted to the pharmacy requesting repayment of costs and reimbursement amounts associated with adjudicating the fraudulent claims. 
     The prescription records may be derived from various data sources. The data sources may have information on these healthcare participants in different forms and different spellings. In addition, some of the data provided by the data sources may be erroneous. The methods and systems may determine from among the information received what is most valuable and likely correct and promote, or highlight, this information. The promoted information may be used for display, analysis, or the like. 
       FIG. 13  illustrates an example transformation subsystem  1300  that may be deployed in the data query device  102 , the data manager device  106 , the data analysis device  108 , the benefit manager device  110 , the data supplier device  112 , combinations thereof, or otherwise deployed in another system. One or more modules are communicatively coupled and included in the transformation subsystem  202  to enable claims data processing. The modules of the transformation subsystem  202  that may be included are a source data module  1302 , a data comparison module  1304 , a priority determination module  1306 , a timing module  1308 , a reference data module  1310 , a data mapping module  1312 , a master data module  1314 , a query module  1316 , and an analysis module  1318 . Other modules may also be included. 
     In some embodiments, the modules of the transformation subsystem  202  may be distributed so that some of the modules are deployed in one of the devices  102 ,  106 ,  108 ,  110 ,  112  and other modules are deployed one or more of the devices  102 ,  106 ,  108 ,  110 ,  112 . In one embodiment, the modules are deployed in memory and executed by a processor coupled to the memory. The functionality contained within the modules  1302 - 1318  may be combined into a lesser number of modules, further divided among a greater number of modules, or redistributed among existing modules. Other configurations including the functionality of the modules  1302 ,  1318  may be used. 
     The source data module  1302  stores the source data  120  received from a data source. The source data module  1302  compares the source data  120  against the master data  122 . The source data  120  may be received from a single data source or multiple data sources. Examples of data sources include the benefit manager devices  110  and the data supplier devices  112 . Examples of data that the source data module  1302  may store as the source data  120  include the member data  130 , the claims data  132 , the prescription data  134 , the pharmacy data  136 , and the data supplier data  138 . The source data  120  may include information about a particular healthcare participant (e.g., information about a member of a prescription drug plan), or may include information about multiple healthcare participants (e.g., a prescription drug claim including information about a member of a prescription drug plan, a pharmacy that filled the prescription drug claim for the member, and a prescriber that prescribed the prescription drug of the prescription drug claim). 
     In some embodiments, the master data  122  used to compare against the source data  120  is in the form of master records. Examples of master records include prescriber records, pharmacy records, and patient records. In general, each master record is associated with a specific healthcare participant (e.g., a person or an entity). 
     In some embodiments, the source data module  1302  determines that there is no standardized format for the data source. When such a determination has been made, source data  120  that is not in such a format may be transmitted to a device (e.g., the data manager device  106 ) for manual processing. At manual processing, an operator may determine how to modify or otherwise handle such source data  120 . In some embodiments, a device may suggest to the operator the possible changes that may be made (e.g., based on data analytics, past selections, or otherwise). Once manual processing is complete, the device transmits back to the source data module  1302  the standardized format for the data source. 
     Thereafter, the source data module  1302  may, based on receipt of a transmission or from previously stored information, be able to process nonmatching source data by being able to process it into a standardized format. The standardized format may include, by way of example a standardized spelling format, a standardized capitalization format, a wording appearance format, a numbering appearance format, or the like. The standardizations may be specific to a person or entity, or may be generally applicable across a number of people or entities. 
     In some embodiments, the source data module  1302  identifies a source data provider associated with the comparison data and determines whether a source data import from the source data provider has previously been performed. When a determination is made that the source data import has previously been performed, the source data module  1302  selects the standardized format and the standardized field splits format associated with the source data provider. In some embodiments, the source data module  1302  receives a source data transformation to correct a portion of the source data and corrects a portion of the source data with the source data transformation to create a source data portion. While the foregoing generally describes that the formatting of a data source is available based on past usage, the formatting of a data source can change such that additional standardization may be used. 
     In some embodiments, the source data module  1302  defines the transformation by comparing the data attributes included within the received data and the corresponding data attributes included within the master data  122 , and identifying differences between the data attributes, and further identifying modifications necessary to transform the received data attribute to the data attribute included within the master data  122 . Various additional and/or alternative levels of transformation granularity and/or types of transformation may be equally utilized. Further, while a transformation to a last name of a prescribing healthcare professional may be used for example, related transformations may be applied to other data attributes. Names and familial relationships may be used as components to determine FWA risk scores. Therefore, having a correct name for any entity is useful. 
     In some embodiments, identifying a transformation to correct the difference between the one or more than one attributes of the received data and the data attribute included in the master data  122  by the source data module  1302  may include accessing transformation data  126  that reflects multiple data transformations in the source data  120  and the master data  122 . For example, the source data  120  may include a collection of data that may be unverified and/or uncorrected, including incorrect data, data with errors, etc., as well as data that may be correct. Further, the source data  120  may include various transformations (e.g., as the transformation data  126 ) to the unverified and/or uncorrected data that may have been made as a result of verifying or correcting the data. The source data  120  may include data received as claims data  132  (e.g., submitted pharmacy claims, or other claims submitted for coverage and/or reimbursement under a healthcare benefit program), professional licensing data received from profession or state licensing or certification agencies, national provider identifier information, DEA information, drug information received from pharmaceutical companies, financial data received from various sources, etc., as well as various additional and/or alternative information. It will be appreciated that much of the source data  120  may include at least the possibility of inaccuracies, or incorrect data. Once data within the source data  120  has been verified and/or corrected, (e.g., based on additional data sources that may provide verification and/or based on transformations to correct the data to a verified form) the data may be stored within the master data  122 , which may include verified and/or corrected data and, in some embodiments, may be in the form of master records. 
     The system  1300  can produce the master data  122 , which may include similar data as the source data  120 , however the master data  122  may include data that has been verified for correctness, accuracy, and validity. The master data  122  may have been verified by comparing and/or correlating information from various sources, including the member data  130 , the claims data  132 , the data supplier data  138 , as well as verification by internal error correction. Accordingly, the master data  122  may include cleaned member data, cleaned claims data, cleaned provider data, cleaned prescription data, cleaned pharmacy data, or the like, in that the data may be cleaned to remove errors or inaccuracies. 
     The data can be processed using systems and methods described in U.S. patent application Ser. No. 14/484,176, titled SYSTEMS AND METHODS FOR INTEGRATING DATA, and assigned to the present assignee, which is hereby incorporated by reference for any purpose. 
       FIG. 14  illustrates a method  1400  for assessing fraud, waste or abuse potential using risk scores. 
     At  1401 , claims data associated with a patient, a prescriber, or a pharmacy is accessed. The data can be stored at any of the databases (e.g., machine accessible storage) or in a memory in any of the devices described herein. A processor, which is executing explicit instructions, may access certain claims data, used to determine a risk score, and not other data, which is not used to determine a risk score. 
     At  1402 , a device, e.g., a processor, determines if the claims data can be used to determine whether the claims data relates to a fraud, waste or abuse determination. 
     At  1403 , a patient risk predictive model, prescriber risk predictive model or a pharmacy risk predictive model from among a plurality of available predictive models is selected based on a type of risk score to be determined. 
     At  1404 , the patient risk predictive model is used on the claims data to calculate, e.g., on the device or the processor, a patient risk score over a first-time period. 
     At  1405 , the prescriber predictive model is used on the claims data to calculate, e.g., on the device or the processor, a prescriber risk score over a second-time period. 
     At  1406 , the pharmacy predictive model is used on the claims data to calculate, e.g., on the device or on the processor, a pharmacy risk score over a third-time period. 
     At  1407 , at least one of the patient risk score, the prescriber risk score, the pharmacy risk score, or a combination thereof is selected to determine violation of a risk threshold. When a risk threshold is violated, e.g., exceeded, then that risk score is flagged in the system. 
     At  1408 , the risk flag is transmitted to a client device when a risk threshold violation by the risk score is determined. 
     At  1409 , an optional step may be performed. The optional step may be making decision is made whether to further investigate the flagged risk score and the associated patient, prescriber or pharmacy. 
       FIG. 15  is a schematic view of a risk score modeling system  1500 . A claims database  1501  stores data relating to medical data, e.g., prescription drug data or medical services data. This data can be voluminous, e.g., billions of claims each having tens or hundreds of data types for each claim. The data relating to both valid medical data and fraudulent data medical data are stored in the database. The database for prescription data includes patient data, prescriber data, and pharmacy data. The prescription data can be the raw data relating to a prescription claim submitted for adjudication. The prescription data can include approved prescription data that has an approved status output from the PBM to the pharmacy, rejected prescription claims, and reversed prescription claims. The prescription data can also use other data that is stored by the PBM system that is not used to directly adjudicate the prescription claim. An example of this data includes the number of times a specific pharmacy has accessed the PBM system, the number of times a specific patient has tried to fill a type of a prescription (e.g., an opioid, a narcotic, or other frequently abused drug), and other systemic data types that relate to a particular prescription but not used for adjudicating the submitted particular prescription claim. 
     The claims database  1501  can include a prescription drug adjudication database that includes additional data besides adjudication results. The patient risk predictive modeler  1503  accesses the prescription drug adjudication database and discerns a patient risk predictive model using prescription drug data in the database over a first-time period that includes at least one known incident of patient FWA. The first-time period can be months or a year preceding the FWA incident. The selected FWA incident can be a patient FWA incident. The patient risk predictive modeler  1503  identifies the data types in the claims database  1501  that are predictive of FWA. These data types are used as features in the patient FWA predictive mode to be stored in the FWA model storage  1509 . 
     The prescriber risk predictive modeler  1505  accesses the prescription drug adjudication database  1501  and discerns a prescriber risk predictive model using prescription drug data in the database over a second-time period that includes at least one known incident of prescriber FWA. The second-time period can be months or a year preceding the FWA incident. The selected FWA incident can be a prescriber FWA incident. The prescriber risk predictive modeler  1505  identifies the data types in the claims database  1501  that are predictive of FWA by a prescriber. These data types are used as features in the prescriber FWA predictive mode to be stored in the FWA model storage  1509 . 
     The pharmacy risk predictive modeler  1507  accesses the prescription drug adjudication database  1501  and discerns a pharmacy risk predictive model using prescription drug data in the database over a third-time period that includes at least one known incident of pharmacy FWA. The selected FWA incident can be a pharmacy FWA incident. The pharmacy risk predictive modeler  1507  identifies the data types in the claims database  1501  that are predictive of FWA by a pharmacy. These data types are used as features in the pharmacy FWA predictive mode to be stored in the FWA model storage  1509 . 
     The system  1500  can send the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model for storing in storage  1509  and for use in an FWA processor to apply the models to prescription data to determine a likelihood of fraud waste or abuse of a prescription drug system. The application of the models loaded in the FWA processor can be used on data different than the training data used to develop the models. The difference can be a difference in time or a difference in data. The models are portable and can be applied to different data. In an example embodiment, the FWA processor applies at least one of the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model to prescription data at least partially outside the first-time period, the second-time period and the third-time period to predict the likelihood of fraud, waste or abuse of the prescription drug system. 
     Each of the modelers  1503 ,  1505 ,  1507  are used to reduce the number or potential features that equals all of the data types in the database  1501  to a reduced set of features. The features may be different for each of the patient model, the prescriber model and the pharmacy model. The number of features may be a third or less of the total number of data types. The number of features may be a tenth of the total number of data types. The number of features may be an order of magnitude or two orders of magnitude less of the total number of data types. The number of features may be a single digit percentage of the total number of data types, e.g., less than ten percent. The features may include values that are calculated from two or more data types. 
     The FWA processor  1511  can select any of one of the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model among a plurality of available predictive models based on a type of risk score being determined. The processor loads the selected one of the patient risk predictive model, the prescriber risk predictive model, and the pharmacy risk predictive model. The processor can apply any of the models over different time period of data in the database  1501 . When the patient risk predictive model is loaded in the FWA processor  1511 , the FWA processor  1511  uses the patient risk predictive model and the claims data to calculate a patient risk score over a first evaluation time period. When the prescriber risk predictive model is loaded in the FWA processor  1511 , the FWA processor  1511  uses the prescriber risk predictive model and the claims data  1501  to calculate a prescriber risk score over a second evaluation time period. When the pharmacy risk predictive model is loaded in the FWA processor  1511 , the FWA processor  1511  uses the pharmacy risk predictive model and the claims data  1501  to calculate a pharmacy risk score over a third evaluation time period. The evaluation tine periods can be different time periods. In an example, the time periods can be the preceding year, the preceding quarter, or the preceding month. 
     The processor is to compare the calculated one of the patient risk score, the prescriber risk score, the pharmacy risk score, or a combination thereof to determine violation of a risk threshold and to send a risk flag to a client device when a risk threshold violation by the one risk score is determined. The risk flag can be a graphic indicator that a risk score has exceeded a threshold value or that an unacceptable risk has been determined by the FWA processor. 
       FIG. 16  shows a schematic view of a database  1600 , which can be stored in the database  114 . The database  1600  includes a plurality of data types,  1601   1 ,  1601   2 , . . .  1601   N-1 ,  1601   N  that are each a potential feature in at least one of the FWA models. The modelling described herein will filter the data types to decide which of the data types are indicative of potential FWA. In an example, the data types  1601   1  and  1601   N  are included in the model as indicative of FWA; the data types  1601   2  and  1601   N  are excluded from the model. 
     Examples of data types  1601  that become features in the patient model of opioid FWA include benzodiazepine (benzo) consumption, number of unique prescriber and pharmacy combinations per therapy, morphine equivalent dose, opioid claims per pharmacy, refill too soon reject transactions, paid claim amount, sleep claims per pharmacy, number of days between earliest opioid fill and most recent opioid fill, distance traveled for opioids, duplicate therapy claims, number of unique prescribers for control substances, concomitant opioid and suboxone consumption, brand claims, chain pharmacy usage, control substances, emergency room prescriber usage, night claims, claims where the pharmacy and doctor are not in the same state, number of submitted and then reversed transactions, and the like, Data types that are not used as features in this model include age, prior authorizations, specialty drug claims, maintenance utilization, gender, line of business, name, and the like. 
     Examples of data types  1601 , in another example embodiment, that become features in the patient model of opioid FWA include percent of reversed transactions in the past X days, percentage of control substance claims, percentage of claims at chain pharmacy that are opioids, percentage of claims that are brands, average number of unique doctor/pharmacy combinations per generic code number (“gcn”) in the past year, number of duplicate therapy claims, percentage of emergency room doctors who are writing for opioids, number of days between first opioid claim and latest opioid claim, average morphine equivalent dose per day, total distance between the pharmacy and doctor for opioids, average number of refill too soon rejects for opioids per doctor, average number of sleep claims per sleep dispensing pharmacy, average dollar value per paid claim, binary flag of whether the member has taken an opioid and a suboxone prescription in the same thirty day window, percentage of claims where the pharmacy and doctor are not in the same state that are opioids, percentage of night claims that are opioids, average number of opioid claims per opioid dispensing pharmacy in past X days, average number of benzodiazepine claims per benzodiazepine writing doctors, binary flag of quarter over quarter increase in number of unique control substance doctors, and the like. This list is not exhaustive of the features that can be used in the patient risk score model for opioids. 
     The prescriber risk model may include data types  1601  as the features therein, including single source brand claims, distance (prescriber to patient), patient traveling out of state, refill too soon rejects during adjudication, paid claim amount, reversals, morphine equivalent dose, benzodiazepines prescribed, compounded drugs, opioid patient gender, number of pharmacies dispensing control substances, and the like. Other data types may not be part of this model. Examples may include line of business, patient age, prior authorizations, drug utilization review and the like. 
     Data types  1601  used as the features used in a prescriber FWA risk score for opioids may include a number of unique pharmacies dispensing a prescriber&#39;s control substances divided by number of unique pharmacies dispensing all of prescriber&#39;s claims (a computed from value from other data values in the database), percentage of opioid patients at a prescriber who are male, average morphine equivalent dose per day over a prescriber, average number of brand claims per member at a prescriber, percentage of claims that are compounds from a prescriber, average number of claims where the prescriber&#39;s patients are attempting to skip a prescription drug monitoring program, average number of miles between the patients and a prescriber for controls over the past Y days, prescriber&#39;s average paid claim amount, binary flag of whether the prescriber&#39;s morphine equivalent dose is increasing quarter over quarter for the past year, prescriber&#39;s number of refill too soon rejects for opioid prescriptions divided by the number of unique refill too soon reject opioid members, prescriber&#39;s average reversals per member in the past X days, prescriber&#39;s number of benzodiazepine prescriptions in the past year, and the like. 
     Examples of data types  1601 , in another example embodiment, that become features in the pharmacy risk score model of opioid FWA include number of days between service and adjudication, high cost brand medications as fills, percentage of doctors claims that are high cost brand medications, whole number billings, benzodiazepines, control substances, compounding, reversals and the like. Examples of data types not used in the pharmacy risk score model include patient gender, number of doctors, pharmacy state, refill rate and the like. 
       FIG. 17  shows a schematic view of a predictive FWA model  1700  that uses a plurality of features values  1701   1 ,  1701   2 , . . .  1701   M . M equals the number of features selected from the number of data types N, where M is less than N in an example embodiment. In an example embodiment, M is at least an order of magnitude less than N. In an example embodiment, M is at less than one-hundredth of N. That is, at most one out of one hundred data types are used as features in the model. The number of data types can range from thousands to millions or more. Such a large number of data types precludes efficient operation of analyzing all of the data in all of the data types. The present methods and systems select only those data types as features that are determined to be indicators of FWA. The feature value  1701   1  is used in the model and can be numerical value for purposes of computing a score. If the feature value is a binary value or other non-numerical value, then that value is converted to a numerical score for purposes of computing the risk score. The feature value  1701   1  can be modified using at least one of feature impact  1702   1  and feature weighting  1702   1 . The feature impact  1702  is a parameter that indicates that the feature value  1701  with a greater variable value has greater risk score. The feature impact values  1702   1 ,  1702   2 , . . .  1702   M  can be different for each of the feature values  1701   1 ,  1701   2 , . . .  1701   M , respectively. The inverse can also be true, e.g., a lower feature value results in a higher risk score, which can be set by the feature impact value  1702 . The feature impact value  1702  determines how the feature value will be used in the calculation of the risk score. The weighting parameter  1703  provides a fixed weight for the feature values  1701 . The weighting value  1703   1 ,  1703   2 , . . .  1703   M  can be different for each of the feature values  1701   1 ,  1701   2 , . . .  1701   M , respectively. The weighting factor can make relative rankings of the feature values  1701  for use in the risk score. Some features might be determined to have a greater indication of the likelihood of FWA than others, these features may receive a greater weight parameter  1703  than other features  1701 . The weighting parameter  1703  can also be used to normalize the feature values  1701   1 ,  1701   2 , . . .  1701   M  to each other to give more equal weights to features values that have a lower absolute numerical value but have the same predictive capability as another numerical value for another feature (e.g., feature value  1701   2 ) that is less than the weighting for the first numerical feature value  1701   k . Each feature value  1701   1 ,  1701   2 , . . .  1701   M  when modified for impact and weighting results in a feature score  1705   1 ,  1705   2 , . . .  1705   M . The feature score  1705   1 ,  1705   2 , . . .  1705   M  represent the numerical score that an individual feature contributes to overall risk score  1710  for the present, predictive FWA model  1700 . The model  1700  can be any model described herein, e.g., a patient FWA risk model, a patient opioid FWA risk model, a prescriber FWA risk model, a prescriber opioid FWA risk model, a pharmacy FWA risk model, a pharmacy opioid FWA risk model, and the like. The risk score  1710  can be a sum of the features scores  1705   1 ,  1705   2 , . . .  1705   M . The risk score  1710  can be another algebraic function of the features scores  1705   1 ,  1705   2 , . . .  1705   M . 
     The present risk scores can be used to identify drug classes in which there is a greater risk of FWA. The higher the scores in any one of the patient, prescriber, or pharmacy risk score across a time period related to a specific class of drugs may indicate that that type of drug should be reviewed more carefully for possible FWA. This can be flagged in an output from the system, e.g., to a client device  150  or to a display device within the PBM system. The number of risk scores that exceed a threshold and include a drug that is part of a same class can be used to focus FWA investigation efforts. On a normalized basis, a first drug type, e.g., benzo drugs or opioid drugs, may be present in about one-third of the FWA cases. The models can be built to put a greater emphasis on the first drug type, e.g., by increasing the weighting or the feature impact for the features related to the first drug type relative to other drugs. In an example, the weighting for the first drug type can be set at thirty-three times the value of a drug type that has not been part of a FWA incident. Another drug that may need to have a greater emphasis in determining risk scores is gabapentin, which can be a second drug type. On a normalized basis, the second drug type, e.g., gabapentin, may be present in about one-sixth of the FWA cases. The models can be built to put a greater emphasis on the second drug type, e.g., by increasing the weighting or the feature impact for the features related to second drug type relative to other drugs. In an example, the weighting for the second drug type can be set at about sixteen times the value of a drug type that has not been part of a FWA incident. A third drug type, e.g., ADHD medications, can be set at about two times a non-FWA drug type. A fourth drug type, e.g., bupropion, can be set at about three times a non-FWA drug. A fifth drug type, e.g., a muscle relaxant drug, can be set at about eight times a non-FWA drug. The non-FWA drug can be drug type that is least likely to be part of a FWA event. The weight of the non-FWA drug can be set to one times, or the normalization value. 
       FIG. 18  shows a schematic view of the models  1800  that can be derived from known FWA. These models use features that are determined from data that predates the known FWA. The data types that are predictive of the FWA are used as features in the predictive model. The predictive models include, but are not limited to a patient model  1801 , a prescriber model  1802 , and a pharmacy model  1803 . Each of these can be used to calculate a risk score. The models  1801 ,  1802 , and  1803  can also each include sub-models. The sub-models  1806   1 , . . .  1806   N  are sub-models that are all patient risk models. The patient sub-model  1806   1  can be directed to evaluate a patient opioid risk score. The patient sub-model  1806   N  can be directed to evaluate a different patient risk score than the patient opioid risk score. The sub-models  1807   1 , . . .  1807   N  are sub-models that are all prescriber risk models. The prescriber sub-model  1807   1  can be directed to evaluate a prescriber opioid risk score. The prescriber sub-model  1807   N  can be directed to evaluate a different prescriber risk score than the prescriber opioid risk score. The sub-models  1808   1 , . . .  1808   N  are sub-models that are all pharmacy risk models. The pharmacy sub-model  1807   1  can be directed to evaluate a pharmacy opioid risk score. The pharmacy sub-model  1807   N  can be directed to evaluate a different pharmacy risk score than the pharmacy opioid risk score. 
     The sub-models can be directed to individual pharmacy benefit plans. In en example embodiment, a set of sub-models for each of patient risk model, prescriber risk model, and pharmacy risk model can be determined for each of Medicare, Medicaid, Department of Defense (DOD) plan, commercial health plans. Thus, each of these can have a sub-model specific to the FWA that may occur in each individual plan. Some features may overlap between sub-models for these individual plans. Each plan may have at least one feature that occurs in its plan, e.g., a DOD directed risk sub-models, and not in other plans, e.g., a commercial plan. 
     In an example, the features used in the models  1801 ,  1802 ,  1803  may depend on geographic location, which can be included into the data. Different FWA may be more likely to occur in certain locations. For example, FWA in a first location, e.g., New York City, may involve high-cost, single-source medications, e.g., Abilify or Seroquel. A sub-model  1806 ,  1807 ,  1808  for any of the patient risk score model, a pharmacy risk score model and the pharmacy risk score model may be developed that weighs the single source medication more heavily when any of the patient, prescriber, or pharmacy is in New York City. The sub-model may be different between the patient model, the prescriber risk model and the pharmacy risk model. The development of the models described herein may determine that the pharmacy location is not a feature for pharmacy risk score model, but is a feature for the patient and pharmacy risk score models. Moreover, the weighting of the single source medication may be different in each model. In developing the pharmacy model, it may be determined that a pharmacy in a second location, e.g., recently in Florida, phantom pharmacies are a greater risk than in other locations in the United States. A phantom pharmacy is a pharmacy that sets up shop, bills as much as it can for as long as it can and then will disappear. Thus, a location in Florida, based on historical data, may be a feature that weighted more heavily or included at all in a pharmacy FWA risk score model. 
     The FWA predictive risk models can include a plurality of features, these features can be individual to one of the predictive risk models. Some of the features may overlap, e.g., a location feature may be used across more than one predictive risk model. The pharmacy risk predictive model may include a plurality of features to calculate the risk score. These features can include service and adjudication feature, a high cost brand medications feature, a whole number billing feature, a benzodiazepine feature, a control substance feature, a compounding feature, and a reversals feature. The patient predictive risk model may include a benzodiazepine consumption feature, a therapy feature, a morphine equivalent dose feature, a pharmacy feature, a transactions feature, an amount feature, an opioids feature, a suboxone consumption feature, a chain pharmacy usage feature, an emergency room prescriber usage feature, a reversed transactions feature, and a same state feature. The prescriber predictive risk model may include a service and adjudication feature, a high cost brand medications feature, a compounding feature and a reversals feature. It some example embodiments the reversals feature may be used in more than one predictive risk model. The reversals feature may have different weightings or different feature impact for calculating the risk score for any one of the patient risk score, the prescriber risk score, and the pharmacy risk score. 
     It is useful that the data used to create the risk score is associated with the correct entity. Thus, the claims data can be corrected or standardized before the model is generated or before the model is applied to the data to produce a risk score. 
     The claims data being used to deduce the models or on which the models operate can be data having a plurality of plurality of different types. The claims data includes adjudicated data and claims data that is submitted for adjudicated. The claims data includes prescription data that is rejected or reversed under the adjudication process. The claims data relates to patient, prescriber and pharmacies. The claims data that is used to develop a model can include all of the types of data. The data types that indicate or influence the likelihood of prescription or medical fraud, waste or abuse may be different for each of the plurality of models, e.g., the patient predictive risk model, the prescriber predictive risk model and the pharmacy predictive risk model. There can be some overlap in the types of data for each model. However, the models will have at least one different type of data in an example embodiment. 
     The present description describes various embodiment for producing statistical models to interrogate a large database, e.g., over a billion prescription claim records, which each have tens to hundreds of different types of data associated with each claim and using the statistical models to further investigate the claims data to use a machine to determine likelihood of fraud, waste and abuse. In the past, identifying pharmacy fraud, waste and abuse meant having technicians and data researchers look at patterns of billing to identify outliers. The manual queries looked at whether a pharmacy dispensing too many of certain kinds of drugs and were the reversal rates for prescription refills too high or too low. However, the much effort was wasted looking at the wrong questions or the wrong data resulting too many false positives or allowing a significant amount of FWA to not be uncovered. The use of the present systems and methods determines the types of data that should be looked at and establishes a model that is used to look for FWA patterns and likelihood in the data. The present description can provide further improvements in the understanding of what and who to look for when investigating FWA. The presently described systems and methods provide a new scheme that can only be performed in machines, e.g., due to the volume of data and data types. The features for a FWA risk score model can be automatically determined and then used to identify errors or patterns of fraud and abuse. The present description can be used to identify fraud, e.g., intentionally misusing the prescription drug system for monetary gain, or waste and abuse, e.g., intentionally misusing the prescription drug system. 
     The term “based on” or using, as used herein, reflects an open-ended term that can reflect others elements beyond those explicitly recited. 
     The phrase fraud, waste and abuse refer to excessive, fraudulent, or other nefarious use of the pharmacy drug system, e.g., attempts or successful fraudulent billing or prescription drug acquisition. Such nefarious actions can be for money or for access to restricted medications. Fraud, waste and abuse can be a type of illegal act involving the obtaining of something of value, either reimbursement in the pharmacy drug benefit plan or non-medical access to drugs, through willful misrepresentation. Fraud, waste and abuse can also include overutilization of services or other practices that, directly or indirectly, result in unnecessary costs to the health care system, including pharmacy benefit plans. In some instances, waste may not be criminally negligent actions, but can be a misuse of resources. In some instances, abuse may include payment for drugs or services when there is no legal entitlement to that payment and the individual or entity has not knowingly and/or intentionally misrepresented facts to obtain payment. 
     Certain systems, apparatus, applications or processes are described herein as including a number of modules. A module may be a unit of distinct functionality that may be presented in software, hardware, or combinations thereof. When the functionality of a module is performed in any part through software, the module includes a computer-readable medium. The modules may be regarded as being communicatively coupled. 
     The inventive subject matter may be represented in a variety of different embodiments of which there are many possible permutations. The methods described herein do not have to be executed in the order described, or in any particular order. Moreover, various activities described with respect to the methods identified herein can be executed in serial or parallel fashion. 
     A first example embodiment can use the models to detect a prescription drug fraud, waste or abuse by producing a score in a scoring system. The first embodiment can include a prescription drug adjudication database; a patient risk predictive modeler to access the prescription drug adjudication database and to discern a patient risk predictive model using prescription drug data in the database over a first time period that includes at least one known incident of patient fraud, waste or abuse; a prescriber risk predictive modeler to access the prescription drug adjudication database and to discern a prescriber risk predictive model using prescription drug data in the database over a second time period that includes at least one known incident of prescriber fraud, waste or abuse; a pharmacy risk predictive modeler to access the prescription drug adjudication database and to discern a pharmacy risk predictive model using prescription drug data in the database over a third time period that includes at least one known incident of pharmacy fraud, waste or abuse; and a model storage to receive the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model for storing and for use in applying the models to prescription data to determine a likelihood of fraud waste or abuse of a prescription drug system. 
     The system of the first example embodiment can include the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model being applied to prescription data at least partially outside the first-time period, the second-time period and the third-time period to predict the likelihood of fraud, waste or abuse of the prescription drug system. 
     The system of the any example can include the patient risk predictive modeler identifying types of data in the prescription data that indicate at least one of fraud, waste, abuse, or a combination thereof by a patient and setting patient risk predictive model features to be the types of data. The types of data indicate at least one of fraud, waste, abuse, or a combination thereof is fewer than all types of data. 
     The system of any example embodiment includes the patient risk predictive model features being less than one-third of the types of data. 
     The system of any example embodiment includes the prescriber risk predictive modeler identifying types of data in the prescription data that indicate at least one of fraud, waste, abuse, or a combination thereof by a prescriber and sets prescriber risk predictive model features to be the types of data. The types of data that indicate of at least one of fraud, waste, abuse, or a combination thereof are fewer than all types of data. 
     The system of any example embodiment includes the prescriber risk predictive model features having less than one-third of the types of data. 
     The system of any example embodiment includes the pharmacy risk predictive modeler identifying types of data in the prescription data that indicate at least one of fraud, waste, abuse, or a combination thereof by a pharmacy and setting pharmacy risk predictive model features to be the types of data, wherein the types of data indicate of at least one of fraud, waste, abuse, or a combination thereof are fewer than all types of data. 
     The system of any example embodiment includes the pharmacy risk predictive model features being less than one-third of the types of data. 
     The system of any example embodiment includes a fraud, waste or abuse processor selecting one of the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model among a plurality of available predictive models based on a type of risk score being determined. When the patient risk predictive model is loaded in the processor, the processor uses the patient risk predictive model and the claims data to calculate a patient risk score over a first evaluation time period. When the prescriber risk predictive model is loaded in the processor, the processor uses the prescriber risk predictive model and the claims data to calculate a prescriber risk score over a second evaluation time period. When the pharmacy risk predictive model is loaded in the processor, the processor uses the pharmacy risk predictive model and the claims data to calculate a pharmacy risk score over a third evaluation time period. The processor is to compare a calculated one of the patient risk score, the prescriber risk score, the pharmacy risk score, or a combination thereof to determine a violation of a risk threshold and to send a risk flag to a client device when a risk threshold violation by the one risk score is determined. 
     The system of any example embodiment includes the processor determines the violation of the risk threshold by determining if a rate of change of the risk score over a fourth-time period exceed a rate threshold. 
     The system of any example embodiment includes the processor determines the violation of the risk threshold by determining if the risk score and an audit discrepancy both increase at a first rate and a second rate over a time period. 
     The system of any example embodiment includes the pharmacy risk predictive model includes features for calculating the pharmacy risk score of: a number of days between service and adjudication feature, a high cost brand medications as fills feature, a percentage of doctors claims that are high cost brand medications feature, a whole number billing feature, a benzodiazepine feature, a control substance feature, a compounding feature, and reversals feature. 
     The system of any example embodiment includes the pharmacy risk predictive model does not including a patient gender feature, a number of doctors feature, a pharmacy state feature, or a refill rate feature. 
     The system of any example embodiment includes the patient risk predictive model being a patient opioid risk predictive model that includes at least one of a benzodiazepine consumption feature, a number of unique prescriber and pharmacy combinations per therapy feature, a morphine equivalent dose feature, an opioid claims per pharmacy feature, a refill too soon reject transactions feature, a paid claim amount feature, a sleep claims per pharmacy feature, a number of days between earliest opioid fill and most recent opioid fill feature, a distance traveled for opioids feature, a duplicate therapy claims feature, a number of unique prescribers for control substances feature, a concomitant opioid and suboxone consumption feature, a brand claims, feature a chain pharmacy usage feature, a control substances feature, an emergency room prescriber usage feature, a night claims feature, a claims where the pharmacy and doctor are not in the same state feature, a number of submitted and then reversed transactions feature, or combinations thereof. 
     The system of any example embodiment includes patient opioid risk predictive model that does not include an age data type, a prior authorizations data type, a specialty drug claims data type, a maintenance utilization data type, a gender data type, a line of business data type, a name data type, as features. 
     The system of any example embodiment includes the prescriber risk predictive model being a prescriber opioid risk predictive model that includes at least one of a number of days between service and adjudication feature, a high cost brand medications as fills feature, a percentage of doctors claims that are high cost brand medications feature, a whole number billings feature, a benzodiazepines feature, a control substances feature, a compounding feature, a reversals feature. and combinations thereof. 
     The system of any example embodiment includes the prescriber opioid risk predictive model not including a patient gender data type, a number of doctors data type, a pharmacy state data type, or a refill rate data type. 
     An example embodiment includes a system for determining drug fraud, waste or abuse scoring. The system can include a data storage device configured for storing a plurality of predictive risk models including an individual risk predictive model, a prescriber predictive model, and a pharmacy risk predictive model, the plurality of predictive risk models being derived from statistically significant script data types in a benefit manager database working backward from known incidents of fraud, waste or abuse; and one of a data query device, a data analysis device, a data manager device, a benefit manager device, and a data supplier device configured for loading one of the plurality of risk models and accessing the benefit manager database. The device is configured to select a patient risk predictive model, prescriber risk predictive model and a pharmacy risk predictive model from the plurality of predictive risk models based on a type of risk score being determined; reduce the statistically significant script data types stored it the data storage device by including only the statistically significant script data types that indicate fraud, waste, or abuse; calculate a patient risk score over a first time period using the patient risk predictive model and claims data in the benefit manager database; calculate a prescriber risk score over a second time period using the prescriber predictive model and the claims data; calculate a pharmacy risk score over a third time period using the pharmacy risk predictive model and the claims data; and determine violation of a risk threshold by at least one of the patient risk score, the prescriber risk score, and the pharmacy risk score. 
     The system of any example embodiment includes the processor being configured to send a risk flag to a client device when a risk threshold violation by at least one of the patient risk score, the prescriber risk score, and the pharmacy risk score is determined. 
     The system of any example embodiment includes the processor wirelessly transmitting the risk flag to the client device. 
     The system of any example embodiment includes the processor being configured to receive a reply from the client device to trigger a fraud, waste or abuse investigation. 
     The system of any example embodiment includes the processor being configured to determine a violation of a risk threshold includes determining if a rate of change of the risk score over a fourth-time period exceed a rate threshold. 
     The system of any example embodiment includes the processor being configured to determine the violation of a risk threshold the risk score and audit discrepancies both increase at a first rate and a second rate. 
     The system of any example embodiment includes the processor being configured to determine a decreasing risk score after a pharmacy benefit manager intervention with an increasing amount of billings after a pharmacy benefit manager intervention. 
     The system of any example embodiment includes the processor being configured to determine a violation of a risk threshold includes an increasing risk score and an increasing number of prescription drug claims. 
     The system of any example embodiment includes a viewer loading an application to a client device, wherein the viewer application is configured to provide a graphical user interface to show a risk score flag, the risk score of at least one of a pharmacy, a prescriber, a patient, or combinations thereof, wherein the viewer application is further configured to receive an input to trigger an investigation and send the trigger to a pharmacy benefits manager device. 
     An example embodiment is directed to a fraud, waste and abuse evaluation system. The system can include a memory storing claims data associated with a patient, a prescriber, or a pharmacy and a patient risk predictive model, a prescriber risk predictive model and a pharmacy risk predictive model; and a processor in operable communication with the memory to determine whether the claims data relates to a fraud, waste or abuse determination and if the claims data relates using a type of the claims data as a feature in a one of the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model to which the claims data relates, to select the patient risk predictive model, the prescriber risk predictive model and the pharmacy risk predictive model based on a type of risk score being determined, to calculate a patient risk score over a first time period using the patient risk predictive model and the claims data, to calculate a prescriber risk score over a second time period using the prescriber risk predictive model and the claims data, to calculate a pharmacy risk score over a third time period using the pharmacy risk predictive model and the claims data, and to select at least one of the patient risk score, the prescriber risk score, the pharmacy risk score, or a combination thereof to determine violation of a risk threshold. 
     The system of any example embodiment includes the risk threshold including a numerical risk score threshold. 
     The present disclosure can produce the models using selected data types that are less than the entire data types. The models can detect of fraud, waste or abuse of pharmaceuticals at various steps in the pharmaceutical supply chain. Thus, methods and systems for detection and prevention of fraud, waste and abuse in medical settings and pharmaceutical prescribing, dispensing, and use have been described. The underlying health data, e.g., prescription drug claims data, can be used, at least in part, to calculate a risk score for all parties associated with the health data. The risk score can be used to predict the risk that any single party, either alone or in conspiracy with other parties, may be committing any one of fraud, waste or abuse with regard to the healthcare service or products. 
     The presently described systems and methods can be applied to fraud, waste or abuse detection systems and methods for healthcare. The system may identify those entities within a healthcare managers book of business who are most likely committing some form of fraud, waste and/or abuse (FWA) using a predictive model that is derived from healthcare data that predates a known incidence of FWA. The systems determine the features used to predict FWA from the numerous data types in the database. These features can then be used on present or other data sets and time periods of data to calculate a risk score for FWA. The system uses the model to detect or predict when one or more of the entities (prescribers, pharmacies, patients) is likely involved, directly or indirectly, with FWA. The system can analyze the pharmacy where the prescription claim is submitted, the prescriber who wrote the prescription on the claim, and/or the member who is purportedly taking the prescription on the claim. The systems and methods may rank the entities using risk scores from predictive modeling techniques to provide fraud, waste and abuse risk oversight, which was previously not possible. 
     Although embodiments of the present invention have been described with reference to specific example embodiments, it will be evident that various modifications and changes may be made to these embodiments without departing from the broader spirit and scope of the embodiments of the invention. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.